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 Studies have revealed that elevated levels of iron promote the formation of 
atherosclerotic plaques and may contribute to the disease progression, while zinc was 
found to have a beneficial effect in rabbits. Guinea pigs have been suggested to be a 
realistic animal model for studying atherosclerosis, as their plasma lipoprotein profile 
closely mimics that of humans. This study initially attempted to further investigate the 
changes in iron and zinc levels in the atherosclerotic plaque, elemental and 
biochemical changes in the intima during initiation and progression of atherosclerosis 
over time and cause-consequence relationship between oxidative stress and 
atherosclerosis. For that purpose, male guinea pigs were fed a moderate cholesterol 
(10% fat, 0.17% cholesterol) or high cholesterol diet (10% fat, 0.33% cholesterol) 
alongside controls (4% fat, no cholesterol) for 2, 4, or 6 months.   
 
We found that dietary cholesterol significantly raised the cholesterol 
concentrations in plasma and liver. Plasma and liver cholesterol oxidation products 
(24-OH cholesterol, 7α-OH cholesterol, 7β-OH cholesterol and 7-ketocholesterol) 
were also elevated in cholesterol-fed groups. However, there was no significant 
change in plasma and liver lathosterol, F2-isoprostanes or arachidonic acid levels. 
Unfortunately the diets failed to significantly alter atherosclerotic burden in the 
animals although iron/zinc concentrations within the few lesions (possibly early 
plaques) observed were suggestive of early atherosclerotic plaque formation and 
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consistent with previous data. It may be that previous work on cholesterol-induced 
atherosclerosis in the guinea pig model in the literature could be questionable.  
 
On the other hand, significant liver damage and indications of advanced fatty 
liver disease were observed, together with decreased plasma hepcidin and transferrin 
levels in cholesterol-fed groups. Liver iron and cholesterol were shown to be 
increased in cholesterol-fed groups and a high correlation between them was observed. 
Plasma iron levels were shown to be increased, probably due to decreased plasma 
hepcidin. No significant difference was shown in liver ferritin, transferrin receptor-2 
levels and heme oxygenase-1 activities between the three dietary groups. Liver 
hemosiderin depositions were found in cholesterol-fed groups but not in control group, 
which, together with almost normal oxidative stress levels, suggests that the excess 
iron was safely sequestered in hemosiderin.  
 
Thirdly, spleen enlargement was also found in cholesterol-fed groups, which 
could be explained by possible portal vein hypertension, consistent with the findings 
of increased liver collagen levels in those animals. There was a continuous rise in 
spleen iron with age in all groups, but no significant difference in spleen total iron 
levels was found between the groups. Spleen heme levels significantly decreased in 
high cholesterol group. However, spleen hemosiderin deposition was seen in all 
groups and no significant difference was found between them.     
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Cardiovascular disease is the leading cause of mortality in the world, with an 
estimated 17.3 million deaths in 2008, which was 30% of all global deaths (World 
Health Organization). In Singapore, cardiovascular disease accounts for one third of 
the mortality which claims nearly 5,500 deaths annually (2009, Ministry of Health, 
Singapore).  
 
Due to the high prevalence of cardiovascular disease in the western world, 
intensive studies on this disease have been conducted since 1950’s. After several years 
of investigation, cholesterol has become well known for its causal role in the 
development of atherosclerosis. However, nowadays, cardiovascular disease is still 
the leading cause of mortality in the world (World Health Organization). More 
investigations are required in this area.  
 
Besides cardiovascular disease, cholesterol is also thought to be related to several 
other diseases, such as non-alcoholic fatty liver disease (Wouters et al., 2008; 








 Cholesterol was first discovered in bile and gallstones by Poulletier de la Salle in 
1769, and rediscovered by Chevreul in 1815, who named it "cholesterine” (Olson, 
1998). Cholesterol is an important integral component of all mammalian cells, and it 
is required to maintain the membrane order, dynamics and cellular stability. The 
structure of the cholesterol molecule consists of a steroid ring with a polar head and 
non-polar tail (see Figure 1.1). Cholesterol is also required for the synthesis of other 




Figure 1.1 Structure of cholesterol.  
 
Cholesterol is primarily obtained through de novo synthesis (as illustrated in 
Figure 1.2) or from dietary sources. Due to its hydrophobic nature, cholesterol is 
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generally carried by lipoproteins in the circulation. These plasma lipoprotein particles, 
according to their size, density and lipid content, are classified as either chylomicrons 
(CM), very-low-density lipoproteins (VLDL), low-density lipoproteins (LDL), or 
high-density lipoproteins (HDL) (Sjögren et al., 2006). Figure 1.3 gives an overview 
of the in vivo metabolism of lipoproteins. 
 
 
Figure 1.2 De novo synthesis pathway of cholesterol. 
 
Chylomicrons (CM) are formed in intestinal cells by packaging triglyceride and 
cholesterol with apolipoprotein (apo) B48 (Mansbach et al., 2007). CM are then 
secreted into the lymphatic system and finally into the main circulation, where they 
interact with lipoprotein lipase (LPL) and release fatty acids (Mead et al., 2002). The 
remaining components of the CM (CM remnants) are taken up by hepatic LDL 
receptors (LDL-R) or LDL-R-related protein-1 (LRP-1) when LDL-R is absent (Field 
et al., 2000; Yu et al., 2001).  
 
VLDL are usually formed in hepatic cells by packaging triglyceride, cholesterol, 
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and apoB100 and then secreted into the circulation, where they are hydrolyzed by 
LPL and hepatic lipase (HL) to release fatty acids (Demant et al., 1998). The remnant 
of VLDL becomes LDL, and is then internalized and utilized by cells expressing 
LDL-R (including peripheral cells and hepatic cells), which is assisted by an adaptor 
protein (AP) (Sirinian et al., 2005).  
 
Similar to VLDL, HDL are also synthesized in hepatic cells. After secretion into 
the circulation, with the help of apoA1, HDL can interact with ATP-binding cassette 
A1 and G1 (ABCA1 & ABCG1) on peripheral cells, and activate reverse cholesterol 
transport (Ye et al., 2011). This procedure also requires some modification of 
cholesterol in peripheral cells before being taken up by HDL, for example 
esterification by lecithin-cholesterol acyltransferase (LCAT) (Calabresi et al., 2010). 
During the transportation, HDL is remodeled by cholesterol ester transfer protein 
(CETP) which transfers cholesteryl esters from HDL to the apoB-containing 
lipoproteins (Hunt et al., 2009) and the endothelial lipase (LIPG) which hydrolyzes 
phospholipids and facilitates clearance of HDL (Cohen, 2003), before HDL is 






Figure 1.3 Overview of lipoprotein metabolism. CM: chylomicrons; CMR: CM 
remnants; VLDL: very-low-density lipoproteins; LDL: low-density lipoproteins; HDL: 
high-density lipoproteins; LDLR: LDL receptor; LRP1: LDLR-related protein-1; LPL: 
lipoprotein lipase; FA: fatty acids; HL: hepatic lipase; AP: adaptor protein; ABCA1: 
ATP-binding cassette A1; ABCG1: ATP-binding cassette G1; LCAT: 
lecithin-cholesterol acyltransferase; CETP: cholesterol ester transfer protein; LIPG: 
endothelial lipase; SRB1: scavenger receptor class B type 1. 
 
1.2.2 Cardiovascular disease and atherosclerosis 
 
Cardiovascular disease (CVD) encompasses a wide range of cardiovascular 
disorders including, e.g. coronary heart disease (Ades, 2001), hypertension (Piazza et 
al., 2011), cardiomyopathy (Watkins et al., 2011), stroke (Davis et al., 2011), and 
cerebrovascular disease (Yang et al., 2011). However, the most common 
manifestation of cardiovascular disease is atherosclerosis, which is characterized by a 
thickening of the blood vessel wall and often is the primary instigator of other 
cardiovascular pathology. The development of atherosclerosis has been shown to 
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commence even in infancy and progress throughout the life of the person, with or 
without apparent clinical symptoms. Early stages of this disease have even been found 
in the fetus (Napoli et al., 1997).  
 
The impact of cholesterol on the incidence of atherosclerosis is now widely 
understood. A study conducted by Anitchkow and Chalatow in 1913 was one of the 
earliest studies suggesting this relationship, whereby rabbits fed a diet containing egg 
yolks which are rich in cholesterol, developed fatty lesions similar to those found in 
humans (Anitschkow et al., 1913). With further refinements of those dietary 
experiments, researchers finally concluded that cholesterol is a primary instigator of 
lesion development in those animals, which agreed with pathological observations of 
cholesterol accumulation in human atherosclerotic lesions (Libby et al., 2000). Later, 
with the help of ultracentrifugation, lipoproteins were identified, which explained how 
insoluble cholesterol could be transported in blood and body fluids (Gofman et al., 
1966). After that, the famous Framingham study showed epidemiological evidence of 
the relationship between cholesterol and incidence of cardiovascular disease, as well 
as the protective role of HDL and harmful role of LDL (Kannel et al., 1961).  
 
 Despite convincing evidence from an epidemiological aspect, cholesterol 
lowering therapies were not as successful as many expected. Some early cholesterol 
lowering drugs (e.g. clofibrate, cholestyramine) increased non-coronary associated 
mortality despite decreasing coronary-related deaths, ultimately resulting in an 
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unchanged overall mortality (Oliver, 1991).  
 
 Later, the discovery of hydroxymethylglutaryl coenzyme A (HMG-CoA) 
reductase inhibitors vindicated the cholesterol hypothesis. Unlike the previous 
cholesterol lowering therapy, HMG-CoA reductase inhibitors lowered the overall 
mortality in the study populations (Downs et al., 1998) and decreased LDL 
cholesterol levels by 20-60%, increased HDL levels and reduced coronary events by 
up to one-third over a period of 5 years. Current investigations focus more 
appropriately on lowering levels of LDL specifically and also other aspects of 
dyslipidemia (Libby et al., 2000).  
 
 The basic role of cholesterol in the promotion of atherosclerosis is now 
understood. Atherogenesis is initiated by damage to vascular endothelium, which can 
occur by several mechanisms. Endothelial dysfunction allows more plasma LDL to 
enter the vessel wall, which may undergo oxidation. Monocytes are attracted to the 
injured vessel and adhere (through VCAM/ICAM binding to integrins on monocytes) 
to the vessel wall and enter it, where they develop into macrophages. Oxidized LDL 
(ox-LDL) can be recognized via receptors on macrophages (which differ from 
receptors for unmodified LDL), and are taken up by them (Parthasarathy et al., 1992). 
The uptake of ox-LDL by macrophages results in an accumulation of cholesterol ester 
within the cells, forming lipid droplets. This eventually causes the macrophage to 
develop into foam cells, which are evident in early atherosclerotic lesions. The 
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engulfed ox-LDL may undergo further oxidation and eventually the foam cells die 
forming a necrotic core as seen in more advanced atherosclerotic lesions (Ball et al., 
1995).  
 
 Since ox-LDL uptake is known to lead to foam cell formation and further 
inflammatory cell recruitment, role of oxidative stress in LDL oxidation and 
atherosclerosis became an area of interest, termed as the “oxidative modification 
hypothesis” for the development of atherosclerosis.  
 
1.2.3 Non-alcoholic fatty liver disease 
 
Non-alcoholic fatty liver disease (NAFLD) is a collective term for a range of 
related hepatic disorders including simple steatosis, non-alcoholic steatohepatitis 
(NASH), cirrhosis, and hepatocellular carcinoma. Compared to cardiovascular disease, 
NAFLD is much less well-studied. NAFLD is increasingly recognized as one of the 
most common causes of chronic liver disease, with a prevalence of up to 30% in 
developed countries (Smith et al., 2011). NAFLD is considered to be the hepatic 
event of metabolic syndrome, and is linked to obesity, insulin resistance, type 2 
diabetes, hypertension, and dyslipidemia (Marchesini et al., 2008).  
 
Cholesterol is also considered an important risk factor for NAFLD (Wouters et al., 
2008; Subramanian et al., 2011). Studies by Yasutake et al. showed that dietary 
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cholesterol intake was more important in the onset and progression of NAFLD in 
non-obese NAFLD patients (Yasutake et al., 2009). Unlike obese patients, non-obese 
NAFLD patients usually do not have excessive energy intake and insulin-resistance, 
but have an excessive dietary cholesterol intake (as well as lower dietary 
polyunsaturated fatty acids) (Yasutake et al., 2009).  
 
Previous studies from the same group suggested an important role of the liver X 
receptor α (LXRα)-sterol regulatory element binding protein-1c (SREBP-1c) pathway 
in development of NAFLD in non-obese patients (Higuchi et al., 2008; Nakamuta et 
al., 2009). LXRα belongs to the liver X receptor (LXR) subfamily which is 
ligand-activated transcription factors of the nuclear receptor superfamily. LXRα is 
only expressed in spleen, liver, adipose tissue, intestine, kidney and lung (Baranowski, 
2008). LXRα can activate SREBP-1c and carbohydrate response element binding 
protein (ChREBP) which in turn activate several downstream factors (ACC, FAS, 
SCD-1). Activation of those factors would increase the synthesis of fatty acids in liver 
which may lead to hepatic steatosis and later hypertriglyceridemia (see Figure 1.4 for 
an illustration of the pathway) (Baranowski, 2008). Excessive intake of dietary 
cholesterol could increase the levels of cholesterol oxidation products (or oxysterols), 
which are the ligands of LXRα and could hence activate the 
LXRα-SREBP-1c-pathway leading to an increase in fatty acid synthesis and fat 




Besides the above mechanisms, previous studies have also suggested that 
cholesterol is involved in elevating hepatic inflammation, which may result in the 
development of simple hepatic steatosis to steatohepatitis (Wouters et al., 2008; 
Subramanian et al., 2011). 
 
 
Figure 1.4 LXRα mediated lipogenesis which leads to hepatic steatosis. ACC: 




1.3 Oxidative stress 
 
1.3.1 What is oxidative stress? 
 
 Oxygen can form several reactive species, such as hydroxyl radicals (OH˙), 
superoxide radicals (O2˙
–
), and peroxyl radicals (RO2˙). These species “capable of 
independent existence that contains one or more unpaired electrons” are defined as 
“free radicals” (Halliwell, 2007). Since there are also some reactive derivatives of 
oxygen which are non-radicals, such as H2O2, hypochlorous acid (HOCl), and ozone 
(O3), another concept, “reactive oxygen species” (ROS) was thus introduced to 
describe all radical and non-radical reactive oxygen derivatives.  
 
 Mitochondria are the major source of ATP production in most aerobic organisms. 
However, the mitochondrial electron transport chain (ETC) is also major source of 
dangerous free radicals in vivo due to electron leakage during transportation leading to 
the formation of O2˙
–
 (Saborido et al., 2005; Guidot et al., 1993). Superoxide 
dismutase (SOD) is responsible for the dismutation of O2˙
–
 to H2O2 and H2O 
(McCord et al., 1988; Fridovich, 1995).  
 
Many different antioxidant systems have evolved to defend against ROS. These 
include SOD (McCord et al., 2005), catalase (Bai et al., 2001), glutathione peroxidase 
(GPx) (Lubos et al., 2011) and glutathione (GSH) (Marí et al., 2009), thioredoxin and 
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peroxiredoxins (Miranda-Vizuete et al., 2000), and also metal ion sequestration 
systems. 
 
Normally, the body is able to maintain a balance between antioxidant defences 
and the generation of ROS, however, despite this ROS-mediated damage still occurs 
in vivo. One of the possible reasons for this is that ROS may play essential roles as 
signaling factors (Forman et al., 2002). Similar to phosphorylation and 
dephosphorylation, oxidation and reduction of biomolecules was found to be an 
equally important mechanism of cell signaling (Chiarugi et al., 2007).  
 
In abnormal situations or disease states, this ROS-antioxidant balance may tip the 
scales in favor of the former. When excessive ROS overcomes the available 
antioxidants, the biological system is under a state of “oxidative stress”. Oxidative 
damage to biomolecules, especially DNA, may lead to death of the cell (see section 
1.3.4 for more discussion).  
 
1.3.2 Role of oxidative stress in disease 
 
ROS are known to play a role in initiation and progression of a wide range of 
disorders which may lead to damage of cells or tissue. Similarly, oxidative stress is 




1.3.2.1 Role of oxidative stress in cardiovascular disease.  
 
Previous research has demonstrated the role of the mitochondrial respiratory chain 
and enzymes such as NADPH oxidase, xanthine oxidase, lipoxygenase, nitric oxide 
synthase, and myeloperoxidase in promoting CVD (Sugamura et al., 2011). However, 
the key evidence supporting the view that oxidative stress is important in CVD stems 
from studies of ox-LDL. Unlike normal LDL, ox-LDL is recognized by macrophages 
via scavenger receptors (Parthasarathy et al., 1992). Uptake of ox-LDL results in 
continuous accumulation of cholesteryl ester droplets in macrophages, leading to the 
formation of foam cells. However, ox-LDL is harmful to foam cells, and imposes 
oxidative stress on the cell. Excessive ox-LDL accumulated in foam cells can lead to 
cell death by apoptosis or necrosis (Ball et al., 1995). Secondly, ox-LDL may also be 
taken up directly by endothelial cells via lectin-like oxidized LDL receptor-1 (LOX-1) 
(Maingrette et al., 2005; Sawamura et al., 1997). This direct uptake of ox-LDL by 
endothelial cells may result in endothelial damage, which is a primary event for 
atherogenesis (Li et al., 2003), and it may thus favor atherosclerosis development. It 
is thought that the most damaging state of LDL is when they are in early stages of 
oxidation (minimally modified LDL) whereby they can still bind to LDL receptor. 
Upon further oxidation, they would be recognized by macrophages via scavenger 
receptor and removed by them (Levitan et al., 2010). Unlike unmodified LDL, 
minimally oxidized LDL may activate monocyte chemoattractant protein 1 (MCP-1) 
and macrophage colony-stimulating factor (MCSF), leading to an increase in 
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inflammatory cell recruitment (Berliner et al., 1992).  
 





) (Yuan et al., 1998). These metal ions accelerate lipid oxidation by 
catalyzing formation of OH
· through Fenton chemistry (Liochev et al., 1999) or by 
decomposing lipid peroxides to peroxyl and alkoxyl radicals (Halliwell, 1991).  
 
1.3.2.2 Non-alcoholic fatty liver disease.  
 
In simple hepatic steatosis, lipid droplets which mainly consist of triglyceride 
could be observed in the cytoplasm of hepatic cells (Cohen et al., 2011). While 
development of hepatic steatosis in non-obese patients is related to high dietary 
cholesterol intake and LXRα (see section 1.2.3 for details), hepatic steatosis in obese 
patients has a different mechanism of disease development (Figure 1.5). Obese 
NAFLD patients usually have excessive energy intake and insulin-resistance 
(Yasutake et al., 2009). Firstly, accumulation of fatty acids could be promoted by 
excess intake of triglycerides from the diet. Secondly, glucose levels could be 
increased due to excess dietary sugar intake, causing the increase of insulin levels 
which in turn increases the de novo lipogenesis in liver through activation of ChREBP 
(for glucose) or SREBP-1c (for insulin) (Denechaud et al., 2008; Ferré et al., 2010), 





Figure 1.5 Diets rich in fat and glucose can lead to hepatic steatosis. TG: triglyceride; 
CM: chylomicron; SREBP-1c: sterol regulatory element binding protein-1c; ChREBP: 
carbohydrate response element binding protein. 
 
Simple hepatic steatosis is benign and self-limiting. However, some cases of 
hepatic steatosis may progress further to NASH, which is characterized by hepatic 
cell ballooning and cell death, increased inflammation and/or fibrosis in the liver, 
eventually progressing to liver cirrhosis and carcinoma (Cohen et al., 2011). Although 
the relationship between simple hepatic steatosis and NASH remains poorly 
understood, researchers have widely accepted the “two-hit hypothesis”. The first “hit” 
consists of simple hepatic steatosis which mainly increases the sensitivity of the liver 
to secondary insults, while the second “hit” includes oxidative stress, decreased 
energy production in mitochondria, and inflammation, in which mitochondrial 
oxidative stress plays a central role (Rolo et al., 2012).  
 
When the accumulation of fat in hepatocytes (due to excessive dietary intake of 
fat or de novo lipogenesis) exceeds the capacity of fat oxidation of mitochondria, the 
16 
 
mitochondrial ETC complex can be in an over-reduced state, resulting in an increase 
of electron leakage from ETC complex and hence more production of ROS. At the 
same time, due to the inadequate ability to oxidize fatty acid by mitochondria, the 
excess fatty acids would be alternatively oxidized in peroxisomes and microsomes, 
which results in greater production of H2O2, a product of fatty acid oxidation by 
peroxisomes (Foerster et al., 1981). If the mitochondrial antioxidant defense system is 
not sufficient to scavenge the increased ROS, the imbalance of oxidant-antioxidant 
status (oxidative stress) will damage mitochondrial DNA, lipids, and proteins. 
Damage in mitochondria by ROS will further decrease their capability to oxidize fat, 
and further increase ROS generation (Solís Herruzo et al., 2006; Pessayre, 2007; Rolo 
et al, 2012). This mechanism forms a vicious cycle of damage, amplifying 
mitochondrial dysfunction in NASH development. 
 
 
Figure 1.6 Vicious cycle of damage amplification caused by mitochondrial 
dysfunction in NASH development. ETC: electron transport chain. 
 
 In addition to hepatic cell damage due to mitochondrial dysfunction, the 
development of NASH involves inflammatory processes and fibrosis in liver. ATP 
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depletion (due to mitochondrial dysfunction) and oxidative stress (caused by 
over-production of ROS by mitochondria, peroxisomes, and microsomes) could 
damage hepatic cell components and even lead to cell death. At the same time, 
increased lipid peroxidation products (some of which can be extremely cytotoxic) due 
to excess ROS may not only harm hepatic cells, but also diffuse across the cell 
membrane and influence adjacent cells. Lipid peroxidation products and inflammatory 
cytokines released by damaged hepatic cells may activate Kupffer cells (macrophages 
in liver) and hepatic stellate cells (activated hepatic stellate cells can secrete collagen), 
which could contribute to inflammation and fibrosis (further discussed in section 
1.4.2.2; also see Figure 1.9). In addition, tumor necrosis factor-α (TNF-α) secreted by 
adipose tissue, Kupffer cells and hepatic cells could further increase mitochondrial 
dysfunction, forming another vicious cycle in NASH development (Pessayre, 2005; 
Pessayre, 2007; Rolo et al., 2012) (see Figure 1.7 for an illustration).  
 
 
Figure 1.7 Mechanisms leading to hepatic cell dysfunction, inflammation, and 




1.3.3 Markers of oxidative stress 
 
The instability of ROS makes these molecules difficult to measure, especially in 
vivo. However, when studying diseases, it is perhaps more meaningful to measure the 
damage caused by ROS, rather than the ROS themselves. Therefore, instead of 
directly measuring ROS, it is more feasible to measure the end-products of oxidative 
damage to cellular components in vivo (including DNA, lipids, and proteins) as an 
estimation of the oxidative stress levels. 
 
1.3.3.1 Biomarkers of lipid peroxidation.  
 
Among the many biomarkers of lipid peroxidation, isoprostanes (IPs) are the 
most widely used and believed to be the most accurate, including F2-IPs, F3-IPs, and 
F4-IPs (Nikolaidis et al., 2011). Among all the different IPs, F2-IPs are the most 
widely used lipid peroxidation marker, which are the end-products of oxidative 
damage on arachidonic acid (Figure 1.8). F2-IPs are best measured by GC-MS or 
LC-MS with pretreatment “clean up” steps on columns. Most IPs are esterified to 
phospholipids in vivo, which are eventually hydrolyzed to free IPs and metabolized 
quickly. Therefore, it is important to distinguish between total IPs and free IPs in 
measurements (Nourooz-Zadeh, 2008). Many animal and human studies have shown 
increased IPs level in diseases, including cardiovascular disease, diabetes, 
hypertension, liver disease, renal disease, lung disease, reproductive disease, 
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inflammatory disease, and neurodegenerative diseases (Basu, 2008; Morrow, 2006). 
 
 





Malondialdehyde (MDA), derived from lipids as a decomposition product, also 
serves as a biomarker for lipid peroxidation. The thiobarbituric acid assay (TBA assay) 
is a widely-used assay for measuring lipid peroxidation. Free MDA formed during 
lipid peroxidation reacts with TBA, forming a (TBA)2-MDA adduct which absorbs 
light at 532 nm, and can hence be quantified spectrophotometrically (Lykkesfeldt, 
2007). High performance liquid chromatography (HPLC)-based TBA assays have 
been developed to avoid much the interference in the simple TBA assay, which is an 
unreliable biomarker of lipid peroxidation (Seljeskog et al., 2006).  
 
 Besides fatty acids, cholesterol in membranes and lipoproteins can be oxidized 
during lipid peroxidation, forming several products termed cholesterol oxidation 
products (COPs). Some of those COPs are found to be correlated with development of 
atherosclerosis, neurodegenerative disease, and several other diseases (Sottero et al., 
2009), including 24S-OH cholesterol, 27-OH cholesterol, 7α-OH cholesterol, 7β-OH 
cholesterol, and 7-ketocholesterol, although their causative role, if any, has not yet 
been established. 24S-OH cholesterol is produced only in brain, unlike unmodified 
cholesterol, it can diffuse through the blood brain barrier where it is metabolized by 
the liver. 24S-OH cholesterol is one of the ways in which the brain metabolizes the 
excess cholesterol produced through constant de novo synthesis. 24S-OH cholesterol 
was found to be related to β-amyloid and involved in brain vascular function 




 27-OH cholesterol, 7β-OH cholesterol, 7-ketocholesterol, and 7α-OH cholesterol 
are the most abundant oxysterols found in atherosclerotic lesions (Olkkonen et al., 
2004; Björkhem et al., 2002). 27-OH cholesterol also serves as the main metabolic 
pathway of cholesterol in extra-hepatic organs. After formation it is secreted into the 
circulation in lipoproteins, and picked up by liver, where it is further metabolized and 
excreted in the bile (Björkhem et al., 2002). A GC-MS method has been well 
established in our laboratory, to analyze the levels of different COPs in plasma (Lee et 
al., 2008) and other organs (Jenner et al., 2007).  
 
1.3.3.2 Biomarkers of protein damage by RS.  
 
Proteins can be damaged by many species including certain ROS such as OH˙, 
end-products of lipid peroxidation (e.g. MDA, see section 1.3.3.1), and 
glycation/glycoxidation. Among the markers of protein damage by ROS, the protein 
carbonyl assay serves as a good marker for the measurement of oxidative protein 
damage, since it detects a range of modifications. Several ROS and aldehydes can 
oxidize or add to amino acid residues to form carbonyl groups, which can be 
measured after reaction with 2,4-dinitrophenyl-hydrazine (DNPH). Carbonyl groups 
may also be measured by spectrophotometric assay, via ELISA after reaction with 
tritiated sodium borohydride, by immunoassays using anti-DNPH antibodies, or by 
isolation using biotin-binding columns following a reaction with biotin hydrazide and 
identified using fluorescently labeled avidin (Chevion et al., 2000)  
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1.3.4 Management of oxidative stress 
 
Oxidative stress is harmful to organisms due to the damage it may cause to many 
biomolecules critical to the function of the cell. Therefore, organisms have adopted 
several strategies to defend against oxidative damage. 
 
ROS production occurs continuously in healthy cells and plays important roles in 
cellular signaling, which mostly involves oxidation and reduction of –SH groups or 
iron ions. These signaling pathways are often referred to as redox regulation, which 
mediates intracellular signaling (e.g. in response of cells to hormones and growth 
factors; communications between nucleus and mitochondria) (Li et al., 2010; Finley 
et al., 2009), intercellular signaling (e.g. the free radical nitric oxide) (Maulik et al., 
1995; Shono et al., 1996; Poli et al., 1997), and signaling between organs and the rest 
of the body in response to stress. Indeed, when stimulated by low levels of ROS, 
many cells show a response of proliferation, which illustrates the roles of oxidative 
stress in cell cycle signaling (Buettner, 2011).  
 
When facing greater oxidative stress, cells may encounter higher levels of 
oxidative damage and increased levels of metal ions that could facilitate the 
production of free radicals, such as OH˙. In this case, adaptive responses will be 
activated and levels of protective systems will be increased, including antioxidant 
enzymes, heme oxygenase-1 (HO-1), and ferritin which help sequester iron. These 
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protective responses will help protect important molecules, and render the cell more 
resistant to oxidative stress (Crawford et al., 1994). The cell cycle often halts in this 
case to allow repair of DNA damage (Flattery-O'Brien et al., 1998). 
 
When oxidative stress is too high and protection systems fail, there can be severe 
mitochondrial and DNA damage, which would initiate apoptosis (programmed cell 
death) or necrosis (when under extreme oxidative stress) (Loh et al., 2006). While, 
cell undergoing apoptosis remain intact, whilst in comparison necrotic cells release 
their contents into the surrounding area, influence adjacent cells, and may stimulate 
inflammation (Fink et al., 2005).  
 
1.4 Iron and its role in oxidative-stress-induced damage 
 
1.4.1 Role of iron in the body 
 
Iron is an essential element which plays many important roles in our body. The 
majority (about 60-70%) of body iron exists in hemoglobin, with another 10% of total 
body iron in myoglobin (a protein which serves as an oxygen store and facilitates 
intracellular oxygen transport), cytochromes, and other iron-containing enzymes, 
while the rest is stored as ferritin and hemosiderin (Lieu et al., 2001).  
 
In the body, iron is typically bound in porphyrin such as heme, which forms the 
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functioning part of hemoglobin, myoglobin, and cytochromes. Fe
2+
 (as in ferrous 
heme) can bind to oxygen and therefore serves as carrier of oxygen (as in hemoglobin, 
the main transporter of oxygen in our body) (Kurz et al., 2011). Cytochrome c oxidase 
is an important part of the ETC which is the main energy source of our body. 





cytochromes) helps to transport electrons and finally produce ATP (Sligar, 1976).  
 
Some antioxidants, such as catalase, also contain heme iron (Sugadev et al., 
2011). Myeloperoxidase (MPO) contains iron in a modified heme structure. MPO is 
involved in the process of killing bacteria by macrophages (Furtmüller et al., 2006). 
Iron is also an important part of a family of heme proteins, cytochromes P450, which 
are powerful oxidizing enzymes (Bondy et al., 1994) that play important roles in the 
detoxification of foreign substances, especially in liver (Miura et al., 1984).  
 
1.4.2 Role of iron in diseases 
 
Dysregulation of iron metabolism may lead to many diseases, such as iron 
deficiency anemia which affects about 1 in 4-5 people worldwide (mostly women and 
children; Coad et al., 2011), as well as hereditary hemochromatosis and β-thalassemia 
which lead to iron overload and related pathology (Fleming et al., 2012). Evidence 
has also suggested that iron dysregulation also plays a role in cardiovascular disease 




1.4.2.1 Cardiovascular disease.  
 
Besides cholesterol (see section 1.2.2 for detailed discussion), evidence has 
shown that iron also plays a role in the development of atherosclerosis (Brewer, 2007). 
This hypothesis was first proposed by Sullivan (Sullivan, 1981). His concept is based 
on the observation that menstruating women are protected against atherosclerosis 
compared to men of the same age, an advantage which is however lost following 
menopause (Sullivan, 1981). Follow-up studies showed that this protection cannot be 
explained by hormone levels (Sullivan, 2003) and post-menopausal hormone 
replacement therapy also turned out to be only partially effective or ineffective 
(Herrington et al., 2000; Hulley et al., 1998). Data from the Framingham study 
showed that risk of coronary heart disease is equal in women with natural menopause 
or with surgical menopause (Kannel et al., 1976; Gordon et al., 1978). He 
hypothesized that it is menstrual blood (iron) loss, not hormonal changes, that protects 
against atherosclerosis. Several animal studies showed supportive evidence on the 
role of iron in atherosclerosis (Meyers, 2000), although clinical studies revealed 
conflicting results (Kakhlon et al., 2002).  
 
Our previous research demonstrated that there was an increase in concentration of 
iron and a corresponding decrease in concentration of zinc within atherosclerotic 
lesions of rabbits fed a high (1%) cholesterol diet, relative to normal arterial wall (Ren 
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et al., 2003). Treatment of the animals with the iron chelator desferrioxamine was 
shown to decrease iron concentration and atherosclerotic lesion area in cholesterol-fed 
rabbits (Ren et al., 2005). In addition, zinc supplementation was also shown to 
decrease atherosclerotic lesion size, which could be due to inhibition of lipid 
peroxidation (Ren et al., 2006; Jenner et al., 2007). 
 
 Several studies showed iron deposition in human atherosclerotic lesions (Smith et 
al., 1992; Swain et al., 1995; Stadler et al., 2004). Plasma levels of COPs were 
correlated to ferritin levels in Finnish men (Tuomainen et al., 2003). Another 
atherosclerosis risk factor, homocysteine, was found to promote iron-catalyzed 
oxidation of LDL (see section 1.2.2 for discussions on the role of ox-LDL in 
atherosclerosis (Hirano et al., 1994).  
 
However, although a correlation between iron and atherosclerosis is suggested, 
these studies failed to show whether iron is the cause or consequence of the disease, 
and iron deposition could also result from locally-elevated inflammation levels. This 
problem needs to be solved to further establish the role of iron in atherosclerosis. 
 
1.4.2.2 Non-alcoholic fatty liver disease.  
 
Early clinical studies documented increases of serum ferritin and/or transferrin 
saturation, and elevated hepatic iron levels in NASH (Bacon et al., 1994). Later, 
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George et al. (1998) proposed a hypothesis that iron-related liver injury may play a 
role in the development of NASH, and a significant correlation between hepatic iron 
levels and severity of liver fibrosis was observed in their study. In addition, a later 
study by Sumida et al. (2003) also suggested a role of iron in lipid peroxidation and 
fibrogenesis, which is central to the development of NASH. On the other hand, 
several other studies failed to show iron accumulation in NASH patients (Younossi et 
al., 1999; Angulo et al., 1999; Chitturi et al., 2002). Whilst, some of these studies 
demonstrated elevated serum ferritin and transferrin, hepatic iron was not found to be 
increased (Angulo et al., 1999; Chitturi et al., 2002).  
 
 Besides serum and hepatic iron levels, several studies showed positive correlation 
between mutations of the gene HFE (encoding human hemochromatosis protein) and 
NASH/NAFLD, which suggested that mutations of HFE in NASH/NAFLD patients 
would increase the severity of the disease (indicated by liver damage markers such as 
raised serum alanine transaminase and increased liver fibrosis) (Powell et al., 2005; 
George et al., 1998; Bonkovsky et al., 1999; Mendler et al., 1999). One study also 
correlated increased hepatic iron to insulin resistance, which plays a central role in 
development of NASH/NAFLD, such as in triglyceride accumulation in hepatic cells 
or initiation of inflammation (Festi et al., 2004). Although hepatic iron levels were not 
always elevated, one study demonstrated a beneficial effect of iron depletion on serum 
alanine transaminase concentrations and insulin resistance in NAFLD patients, further 




 Although currently evidence for the role of iron in NASH remains controversial, 
iron was shown to play a role in hepatic fibrosis, the key step of the development of 
NAFLD to NASH. Hepatic stellate cells (HSC) are responsible for the development 
of fibrotic liver (Sato et al., 2003). Iron-induced oxidative stress was shown to 
damage Kupffer cells and hepatic cells, which release many factors that activate HSC 
(see Figure 1.9) (Philippe et al., 2007). Elevated iron was also shown to directly cause 
oxidative damage to HSC after entering the cells via the ferritin or transferrin 
receptors (Bridle et al., 2003; Gardi et al., 2002). 
 
 
Figure 1.9 Hepatic stellate cell activation induced by iron-induced oxidative stress. 
Under abnormal situations such as hepatitis C, alcohol abuse, hepatic steatosis, 
hepatic oxidative stress would be enhanced, causing damage to hepatic cells and 
Kupffer cells. Apoptosis of hepatic cells and activation of Kupffer cells (may also be 
activated by hepatic cell apoptosis) would lead to activation of HSC, followed by 




1.4.3 Management of iron in the body. 
 
Iron is redox-reactive and can generate highly reactive OH˙ from H2O2 through 
Fenton chemistry, which may damage important molecules (such as DNA, lipids, and 
proteins) (Lieu et al., 2001). Iron must therefore be carefully handled in vivo to avoid 
oxidative damage (see section 1.3 for detailed discussion).  
 
 Although elemental iron exists abundantly (Kurz et al., 2011), the sources of iron 
capable to be absorbed by humans are limited. Those sources include: inorganic iron 
(mostly from plants), heme-iron (from meat) and ferritin iron (from beans, lentils, 
meat, etc), each of which has a different absorption pathway (Theil, 2011). Inorganic 
iron is usually Fe
2+ 
and is absorbed by intestinal endothelial cells through a divalent 
metal transporter (DMT1) (Kohgo et al., 2008). Heme iron is absorbed by intestinal 
endothelial cells through heme carrier protein 1 (HCP1) and degraded by HO-1 
(Laftah et al., 2008). Absorption of ferritin iron involves clathrin-dependent, 
receptor-mediated endocytosis (San Martin et al., 2008). The iron absorbed is then 
transferred to the vascular side of the intestinal cells and released into the circulation 
via ferroportin, being oxidized to Fe
3+ 
by hephaestin and bound to transferrin for the 





Figure 1.10 Mechanism of iron absorption at intestinal endothelial cells. DMT1: 
divalent metal transporter 1; HCP1: heme carrier protein 1.  
 
Almost all the iron in the circulation is bound to transferrin, which has two Fe
3+
 
-binding sites (Aisen et al., 1978). Transferrin is mainly synthesized in liver (Gomme 
et al., 2005). Although the amount of iron transported with transferrin is less than 1% 
(about 4 mg) of total body iron, it has a turnover rate of about 25 mg/day (Lieu et al., 
2001). About 80% of the transferrin-bound iron is eventually used for hemoglobin 
synthesis in the bone marrow. The iron requirement of hemoglobin synthesis is quite 
high (about 20 mg/day), which also relies on the iron recycling by macrophages (from 
destroying old red blood cells, see Figure 1.11) (Lieu et al., 2001). Many other types 
of cells also take up iron from the circulation via transferrin receptors (Nadadur et al., 
2008).  
 
There are two types of transferrin receptors. Transferrin receptor-1 (TfR-1) is 
responsible for iron uptake in the majority of cells, expression of which is inversely 
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regulated by cellular iron levels through a post transcriptional mechanism (by 
activating iron responsive elements on TfR-1 mRNA). Transferrin receptor-2 (TfR-2) 
is mostly expressed in liver and has a much lower affinity for transferrin (Nadadur et 
al., 2008). Unlike TfR-1, TfR-2 is regulated by plasma transferrin saturation level, 
and increased plasma diferric transferrin could increase the number of TfR-2 by 
stabilizing the receptor protein on the membrane (prevent it leaving the membrane 
and being degraded) (Robb et al., 2004; Johnson et al., 2004). TfR-2 was found to 
play some roles in iron metabolism and regulation of hepcidin levels (see below), 
which could decrease the iron absorption by intestine by degradation of iron 
transporter, ferroportin-1 (Kawabata et al., 2005; Nemeth et al., 2005). In addition, 
TfR-2 can also mediate uptake of both tranferrin-bound iron and 
non-transferrin-bound iron (increased in case of iron overload, e.g. ferric citrate) by 
hepatic cells (Graham et al., 2008). 
 
Besides participating in synthesis of hemoglobin and other iron-containing 
proteins, the excess iron is stored in a protein called ferritin to minimize its toxicity 
yet keep it available for future usage. The major iron storage sites are liver, spleen and 
bone marrow. Under normal circumstances, ferritin is the major iron storage; excess 
iron will lead to increase in ferritin but not in other iron-containing proteins such as 
hemoglobin or myoglobin, while iron deficiency will lead to release of iron from 
ferritin (Harrison et al., 1996). However, in abnormal circumstances such as diseases, 
excess iron may be stored in another form, hemosiderin (although iron is normally 
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stored in form of hemosiderin in macrophages; Hoffman et al., 1991). Unlike ferritin, 
hemosiderin is insoluble, forming irregular large clusters, and iron stored in this form 
is released much slower than ferritin and hence is harder to be re-used by the body. 
Hemosiderin is suggested to be a degradation product of ferritin due to its immune 
reactivity with anti-ferritin antibodies (but much lower than ferritin) (Harrison et al., 
1996). 
  
Possibly due to the importance of iron to our body and limited sources of iron 
available, human beings do not have active mechanisms for excreting iron (Kohgo et 
al., 2008), with only iron loss during the physiologic loss of cells from epithelial 
surfaces or during menstrual bleeding (Hytten et al., 1964). Therefore, if absorbance 
of iron is abnormally increased, excess iron would accumulate in the body, causing 
many problems, e.g. hereditary hemochromatosis, a hereditary disease characterized 
by iron overload and subsequent multi-organ damage including liver, pancreas, heart, 
joints, and the endocrine glands (Bothwell et al., 1998). Iron overload in hereditary 
hemochromatosis results from the impairment of the hepcidin-ferroportin pathway, 
which is caused by mutation of genes encoding proteins involved in this pathway. 
Mutations of HFE gene are responsible for most of the cases (involved in the 
regulation of hepcidin expression; Janssen et al., 2009). The HJV gene (encoding 
hemojuvelin), HAMP gene (encoding hepcidin) and TfR-2 gene (encoding transferrin 
receptor-2) (Gan et al., 2011) can also be mutated. Hepcidin is secreted by liver and 
influences iron absorption at intestinal endothelium by decreasing the iron transporter, 
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ferroportin (so called hepcidin-ferroportin pathway). When hepdicin levels are 
abnormally decreased as in hereditary hemochromatosis and several other diseases 
such as hepatitis C (Nagashima et al., 2006) and alcoholic fatty liver disease (Bridle et 
al., 2006), iron absorption by the intestine will be increased, causing iron overload in 
different organs (see Figure 1.11 for an illustration) (Janssen et al., 2009).  
 
 
Figure 1.11 Control of iron uptake and recycling. Most of the iron required for 
hemoglobin synthesis is from recycling from senescent erythrocytes by macrophages. 
Besides the liver, macrophages also function as major iron stores. The liver-produced 
peptide hepcidin could influence iron absorption at intestinal endothelium by 
decreasing the iron transporter, ferroportin. 
 
1.5 Guinea pig as an animal model 
 





 century, including infectious diseases (Padilla-Carlin et al., 2008), asthma 
(Ricciardolo et al., 2008), shock (Miller et al., 1989), allergy (Verdier et al., 1994) 
and tumor immunology (Blumenthal et al., 1967). In the late 20th century, the use of 
guinea pigs as experimental animal model has been gradually replaced by cheaper and 
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easier-to-keep animals, such as mice and rats. Nowadays, guinea pigs remain to be the 
main source of animal model only in limited areas, such as asthma (Buels et al., 2011; 
Cai et al., 2011), in which they are still viewed as an ideal animal model for studying 
the disease (Ricciardolo et al., 2008).  
 
1.5.1 Guinea pig as an animal model for studying diet-induced atherosclerosis 
 
The most striking similarity between guinea pigs and humans is that for both 
species, most plasma cholesterol is transported in LDL (Fernandez et al., 1989), 
which is the central component in the pathogenesis of atherosclerosis (detailed 
discussion in 1.2.2), while in many other animals most plasma cholesterol is 
transported in HDL (Fernandez et al., 2006). Other than plasma lipoprotein 
cholesterol distribution, guinea pigs show many other similarities with humans as 
summarized by Fernandez (Fernandez, 2001) that is; 1) most cholesterol in guinea pig 
liver is in free form (not esterified) (Fernandez et al., 1992a); 2) guinea pigs have 
plasma CETP (Ha et al., 1982), LCAT (Grove et al., 1991) and LPL (Olivecrona et al., 
1993), all of which are important enzymes in cholesterol metabolism; 3) guinea pigs 
have moderate liver cholesterol synthesis rate (Fernandez et al., 1990); 4) guinea pigs 
cannot synthesize vitamin C and therefore require vitamin C in the diet (Sauberlich, 
1978); 5) female guinea pigs are protected by their hormones from atherosclerosis, e.g. 
female guinea pigs have higher HDL (anti-atherosclerosis) than males, while 
ovariectomized guinea pigs have a similar plasma lipid profile to postmenopausal 
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women (Roy et al., 2000); 6) guinea pigs can respond to exercise by decreasing 
plasma triglyceride and increasing plasma HDL (Fernandez, 2001); 7) guinea pigs 
respond to dietary fat saturation (Fernandez et al., 1992b) and fiber (Fernandez, Lin & 
McNamara, 1995) by changes in plasma LDL; and 8) guinea pigs can respond to 
cardiovascular drug treatment, such as statins (Conde et al., 1996), cholestyramine 
(Fernandez et al., 2000) and apical sodium bile acid transport (ASBT) inhibitors 
(West et al., 2002).  
 
Another important similarity between guinea pigs and humans is that guinea pigs 
can respond to physiological amounts of dietary cholesterol. In early studies on 
diet-induced atherosclerosis, guinea pigs were given a 1-2% cholesterol diet (Bernick 
et al. 1962, Puppione et al. 1971, Sardet et al. 1972, Ostwald et al. 1977, Crocker et 
al. 1979, Drevon et al. 1979, Beck et al. 1980), which equates to a very high 
cholesterol intake in humans (about 7,500 - 15,000 mg/day) and may not represent the 
condition in human diets (Fernandez, 2001), and could also lead to death of guinea 
pigs due to increased destruction of erythrocytes (Puppione et al. 1971). In more 
recent studies, much lower dietary cholesterol (0.08, 0.17, and 0.33%; equivalent to ½, 
1, and 2 times, respectively, of the cholesterol amount synthesized daily endogenously) 
were used, and yielded a dose-dependent increase in plasma total cholesterol and LDL 
cholesterol, which is independent of dietary fat levels (Lin et al., 1992; Lin et al., 
1994; Lin et al., 1995). Another study also claimed that guinea pigs could develop 
early atherosclerotic changes and fatty streaks in aorta after feeding 0.25% dietary 
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cholesterol for 3 months, which equals to the range of 2000 mg/day consumption by 
humans (Cos et al. 2000). 
 
1.5.2 Guinea pig as an animal model for studying diet-induced non-alcoholic 
fatty liver disease 
 
Whilst very few studies used guinea pig to study fatty liver disease, some of these 
studies have demonstrated pathological evidence of hepatic steatosis after feeding the 
animals high cholesterol diets. These include a 1% cholesterol diet for 8 weeks 
(Schwemmer et al., 2000), 0.5% cholesterol diet for 8 weeks (Mihaiu et al., 2009), 
and 0.25% cholesterol diet for 12 weeks (Deogburn et al., 2012). Guinea pigs were 
also found to develop fatty liver during fasting as a result of decreased intake of 
carbohydrates and mobilization of fat as the energy source (Schaeffer et al, 1997).  
 
Previous studies have shown a close relationship between NAFLD and 
atherosclerosis (Loria et al., 2008). Similar to atherosclerosis, several risk factors of 
NAFLD are common for both guinea pigs and humans (Loria et al., 2008), such as 
atherogenic hyperlipidemia (similar lipid metabolism and plasma lipid profile), 
systemic inflammation (similar immunologic response), male gender (female gender 
protected), lack of exercise (similar response to exercise) and high fat diet (similar 
response to dietary fat). All those similarities with humans make guinea pigs a 





1.6 Aims of the study 
 
Several studies have revealed that iron could promote the formation of 
atherosclerotic plaques and may contribute to the development of atherosclerosis 
(Salonen et al., 1992, Giles et al., 1993, Matthews et al., 1997, Nassar et al., 1998, 
Stadler et al., 2004), while zinc was found to have opposite effects (Zago et al., 2001, 
Ren et al., 2003, 2005 & 2006, Jenner et al., 2007). However, those results may not 
be applicable to humans, due to the types of animal models and unphysiological 
feeding conditions used. Therefore, we selected the guinea pig as our choice of animal 
model, due to its many similarities in lipid metabolism to humans and its relatively 
low concentration (more physiological) of dietary cholesterol required to generate 
atherosclerosis (Fernandez et al., 2001, 2006).  
 
The aims of our study were: 
1. To further investigate the relationship between iron, zinc, oxidative damage 
and atherosclerosis using a more relevant (to humans) animal model. Whilst 
there are numerous reports describing atherosclerotic changes (such as plaque 
formation, remodeling of the artery wall, tissue iron content, increase in 
oxidative stress-induced damage) in the vasculature, little is known about the 
progression and inter-relationship of these changes. For example, it is 
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presently unclear whether oxidative stress is a cause or consequence of 
atherosclerotic plaque formation. Our study may give us further insights into 
some of these questions. 
2. To investigate the relationship between dietary cholesterol, iron, oxidative 
damage and NAFLD using a physiologically relevant animal model. Previous 
studies showed controversial results on the role of hepatic iron in NAFLD 
(Sumida et al., 2009). We hope our study could help further clarify this issue. 
3. To investigate possible relationship between NAFLD and atherosclerosis. 
NAFLD and atherosclerosis share many risk factors, and NAFLD could 
independently increase the risk of atherosclerosis (Sookoian et al., 2008). 
However, the underlying mechanism that links them remains unknown. This 






CHAPTER 2  
EXPERIMENTAL PROCEDURES 
 




Three diets (control diet, moderate cholesterol diet and high cholesterol diet) 
were designed in consultation with an animal dietician and prepared by Harlan 
Laboratories, Inc. (Indianapolis, IN, USA). The control diet consisted of 4% fat with 
no added cholesterol, while moderate and high cholesterol diets contained 10% fat 
and 0.17% or 0.33% cholesterol, respectively. The carbohydrate levels were adjusted 
in order to maintain an equal total energy between the three diets. All diets were 
stored at 4C until required. 
 
Peroxidation of fats in the three diets were monitored using the TBARS assay 
(see section 1.3.3.1) both at the beginning and end of the animal trial to ensure there 
were no artifactual data arising from feeding oxidized food. This was important as 
feeding oxidized lipids to animals can induce varied pathological changes (Gabriel et 















Alfalfa Meal (Dehyd.) 17% 361.8 362.1 360.5 
Soybean Meal 48% 0 0 0 
Isolated soy protein 121 121 121 
Wheat, Hard, Whole, Ground 30 30 30 
Corn Starch 150 0 0 
Sucrose 60 60 60 
Maltodextrin 120 120 120 
Cellulose (Fiber) 70 158 158 
Olive Oil 9.6 24 24 
Coconut Oil, hydrogenated 19.6 49 49 
Safflower Oil (Linoleic) 10.8 27 27 
Cholesterol 0 1.7 3.3 
Brewers Yeast Dried FG 10 10 10 
40060 VM, 10 10 10 
Stable Vitamin C (35%) 1.5 1.5 1.5 
87390, Mineral Mix 0.5 0.5 0.5 
Dicalcium Phosphate, FG 
(18.5% P) 
15 15 15 
Magnesium Oxide, FG (58% 
Mg) 
2.2 2.2 2.2 
Sodium Chloride  NaCl 8 8 8 
Total 1000 1000 1000 
    
Protein, % by weight 17.5 17.5 17.5 
Protein, % of kcal 24.6 24.6 24.6 
Carbohydrate, % by weight 40.9 27.4 27.4 
Carbohydrate, % of kcal 57.4 38.5 38.5 
Fat, % by weight 5.7 11.7 11.7 
Fat, % of kcal 18.0 36.9 36.9 
Estimated crude fiber 15.9 24.6 24.6 







68 male Harley guinea pigs from the Center for Animal Resources, National 
University of Singapore, weighing 250-500g, were randomly assigned to one of the 
ten groups for 0, 2, 4 or 6 months. Animals in 2, 4 and 6 month feeding durations 
were further assigned to control, moderate cholesterol or high cholesterol diet groups. 
Animals were caged in pairs in a light cycle room (light from 7am to 7pm) and 
allowed free access to food and water. They were acclimatized for 5 days prior to 
commencement of the study. Body weights were recorded on alternate days. At 
sacrifice, blood samples were collected by cardiac puncture into Na-EDTA blood 
tubes primed with 15 μl of 5 mM indomethacin prepared in ethanol from non-fasted 
guinea pigs following anaesthesia by isoflurane inhalation. Plasma was separated 
immediately by centrifugation at 1,500 g, 4 °C for 10 min and then placed into tubes 
with 2 mM butylated hydroxytoluene (BHT) prepared in ethanol (20 μl/ml plasma) 
and stored at -80 °C. Animals were euthanized in a CO2 chamber and aorta was 
dissected, divided into 3 sections and mounted for cryo-sectioning. (section A: from 
start to before carotid artery; section B: 10mm-length artery from after carotid artery; 
section C: 10mm-length artery after section B). Heart, liver and brain were also 
collected, weighed, snap frozen in liquid nitrogen and stored at -80 °C. All the 
procedures were approved by National University of Singapore, Institutional Animal 






All reagents were purchased from Sigma-Aldrich (St. Louis, MO, USA) unless 
otherwise stated.  
 
8-iso-PGF2α-d4, IPF2α-VI-d4, and arachidonic acid-d8 were purchased from 
Cayman Chemicals (Ann Arbor, MI, USA). 7β-OH cholesterol-d7, 7α-OH 
cholesterol-d7, 26(27)-OH cholesterol-d5, 7-ketocholesterol-d7, and lathosterol-d4 
were purchased from CDN Isotopes (Quebec, Canada). 24-OH cholesterol-d7 was 
purchased from Medical Isotopes, Inc (Pelham, USA). Formic acid (Lancaster, 
England), ammonium hydroxide, potassium hydroxide, BHT, hydrochloric acid 
(Merck, Darmstadt, Germany), and hexane (Tedia, OH) were of analytical grade. 
Methanol (EM Science, Darmstadt, Germany) and ethyl acetate (Fisher Scientific UK) 
were of HPLC grade. N,O-bis(trimethylsilyl)trifluoroacetamide+1% 
trimethylchlorosilane (BSTFA+1%TMCs) silylating agent was obtained from Pierce 
Chemicals (Rockford, IL, USA). Pentafluorobenzylbromide (PFBBr) and 
N,N-diisopropylethylamine (DIPEA) were purchased from Sigma Chemicals. Oasis 
mixed anion-exchange cartridges were from Waters Corp. (Milford, MA, USA) 
 
Saliva ELISA kit was purchased from Salimetrics LLC (PA, USA). M-1 
embedding matrix for cryo-sectioning was purchased from Thermo Fisher Scientific 
Inc. (MA, USA). Cholesterol assay kit, protein carbonyl assay kit, and ALT activity 
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kit were purchased from Cayman Chemical (Cayman Chemical, Ann Arbor, MI, 
USA). A HDL and LDL/VLDL cholesterol quantification kit was purchased from 
Biovision Inc. (California, USA). Guinea pig Transferrin ELISA kit was purchased 
from antibodies-online GmbH (Aachen, Germany). Guinea pig hepcidin ELISA kit 
was purchased from Novatein Biosciences (Cambridge, MA, USA). Guinea pig 
ferritin ELISA kit and guinea pig transferrin receptor-2 ELISA kit were purchase from 
MyBioSource, LLC (San Diego, CA, USA).  
 
2.3 Assays and analytical methods 
 
2.3.1 TBARS Assay 
  
TBARS Assay for diet. About 10 mg of crushed animal pellets (exact weight 
recorded) and mixed with phosphate-buffered saline (PBS). The mixture was then 
sonicated for 15 mins. 1mM ferric chloride, 1mM ascorbic acid were added and 
mixture was incubated for 1 hour at 37 °C. BHT (2% w/v in 95% ethanol), 
trichloroacetic acid (TCA, 2.8% w/v), and 2-thiobarbituric acid (TBA, 1% w/v in 
50mM NaOH) were then added and the mixture was incubated at 95 °C for 20 mins. 
1-butanol was added and the mixture was vortexed and left to sit in fume hood for 1 
hour. Absorbance of the organic layer was measured at 532 nm on a microplate reader 




 TBARS Assay for liver. About 20 mg of liver tissue (exact weight recorded) were 
homogenized in 200 l RIPA buffer. The homogenate was sonicated for 15 mins and 
centrifuged at 3,000 g for 10 mins at 4 °C. 100 l supernatant was aliquoted to a new 
1.5 ml micro-centrifuge tube. 200 l ice-cold 10% TCA was added and the mixture 
was incubated for 15 mins on ice to precipitate protein. Samples were then 
centrifuged at 2,200 g for 15 mins at 4 °C. 0 - 100 M malondialdehyde (MDA) 
standards were prepared from 500 M 1,1,3,3-tetramethoxypropane stock (stock was 
prepared by adding 4.167 l 1,1,3,3-tetramethoxypropane into 1 ml ethanol and then 
add 49 ml distilled water). 200 l sample supernatant or standards were aliquoted into 
a new 1.5 ml micro-centrifuge tubes with an equal volume of 0.67% (w/v) TBA. The 
mixture was incubated at 95 °C for 20 mins. After cooling, the absorbance of sample 
and standard were measured at 532 nm on a microplate reader. The results were 
calculated from the calibration curve and normalized to weight of liver sample. 
 
2.3.2 Salivary cortisol measurement 
 
 Saliva samples were collected every 1.5 months by simply letting animals gnaw 
on cotton buds and were stored at -80 °C until analysis. Cortisol concentrations in 
saliva were determined using a saliva cortisol ELISA kit (Salimetrics, LLC, USA). 
Briefly, saliva samples were thawed to room temperature, vortexed, and centrifuged at 
1,500 g for 15 mins. The saliva sample was transferred to clean micro-centrifuge tube. 
25 l of standards, controls (assay diluent), and samples were added into wells of the 
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96 well microtitre plate. 200 l of conjugate diluents (diluted at 1:1600 in assay 
diluents) were then added into each well and the plate was incubated for 1 hour at 
room temperature. The wells were then washed 4 times with 1× wash buffer. 200 l of 
tetramethylbenzidine (TMB) substrate solution was then added into each well and 
plate was incubated in dark at room temperature for 30 mins. 50 l stop solution (3 M 
sulfuric acid) was added after incubation and absorbance was measured at 450 nm 
within 10 mins of adding stop solution. Cortisol concentrations in the saliva were 
calculated according to the standard curve. 
 
2.3.3 Gas chromatography-mass spectrometry 
 
2.3.3.1 Determination of oxidative markers in plasma.  
 
Determination of plasma F2-isoprostanes, arachidonic acid, and COPs using gas 
chromatography-mass spectrometry (GC-MS) was performed using an established 
protocol in our laboratory as described by Lee et al., 2008. Briefly, plasma samples 
were thawed to room temperature and mixed heavy labeled isotopes 0.5 ng 
8-iso-PGF2α-d4, 0.5 ng IPF2α-VI-d4, and 10 µg arachidonic acid-d8 in 20 µl ethanol, 
and COPs heavy isotopes (20 ng 7α-OH cholesterol-d7, 10 ng 7-OH cholesterol-d7, 
20 ng 7-ketocholesterol-d7, 20 ng 24-OH cholesterol-d7, 20 ng 27-OH cholesterol-d5, 
and 0.5 µg lathosterol-d4) in 20 µl ethanol were added into 1 ml plasma samples. In 
order to release esterified lipids, 1M KOH (in 100% methanol) was added into plasma 
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samples, and the tube was flushed with argon gas and sealed. Plasma samples were 
then hydrolyzed at 50 °C for 30 mins. 0.5 ml methanol, 2.5 ml 20mM formic acid 
(pH4.5), and 0.2 ml 5M hydrochloric acid (HCl) were further added into the 
hydrolyzed plasma. 
 
Anionic-exchange solid phase extraction (SPE) cartridges were washed with 2 ml 
methanol and then preconditioned with 2 ml of 20mM formic acid (pH 4.5). After 
loading samples, the column was washed with 2 ml of 2% (v/v) ammonium hydroxide 
and 2 ml of methanol: 20 mM formic acid (pH 4.5) (40: 60 v/v). After the wash steps, 
COPs were eluted with 2 ml of 100% hexane and followed by a further 2 ml of 
hexane: ethyl acetate (70: 30 v/v). F2-isoprostanes and arachidonic acid were eluted 
with 1.6 ml of hexane: ethanol: acetic acid (70:29.4:0.6 v/v/v). The eluted samples 
were evaporated immediately under high-purity nitrogen gas.  
 
For COPs analysis, samples were derivatized with 50 µl pyridine and 50 µl 
BSTFA+1%TMCs at room temperature for 2 hours and then dried under nitrogen gas. 
The derivatized samples were reconstituted in 5 l BSTFA+1%TMCs and 30 l 
undecane before GC-MS analysis. For F2-isoprostanes and arachidonic acid analysis, 
samples were derivatized with 15 µl DIPEA (10% in acetonitrile) and 30 µl PFBBr 
(10% in acetonitrile) at room temperature for 30 mins and dried under nitrogen gas. 
Derivatized samples were reconstituted in 20 l acetonitrile and silylated with 40 µl 
BSTFA+1%TMCs at room temperature for 2 hours, and then dried under nitrogen gas. 
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Then the samples were reconstituted in 40 µl iso-octane and left to sit at room 
temperature for 20 mins. After analysis of F2-isoprostanes with GC-MS, a further 
70µl iso-octane was added and the arachidonic acid content of the samples was 
analyzed with GC-MS. 
 
F2-isoprostanes were analyzed by a Hewlett–Packard 6890 gas chromatograph 
connected with a Hewlett–Packard 5973N mass selective detector. The mass 
spectrometer was set to negative chemical ionization (NCI) mode and the ion source 
and quadrupole were set at 150 and 106 °C, respectively. The flow rates of the carrier 
gases, methane and helium were set to 2 ml/ min and 1ml/ min, respectively. The gas 
chromatograph column used was a fused silica capillary column (30 m × 0.2 mm) 
coated with cross-linked 5% phenylmethylsiloxane (film thickness 0.33 μm). 2 µl 
derivatized sample was injected and the column temperature was kept at 170 °C for 2 
mins, then increased to 275 °C at a speed of 15 °C/ min, kept at 275 °C for 11 mins, 
and then increased to 300 °C at a speed of 25 °C/ min and finally held for 3 mins. Ion 
m/z 569 (for 8-iso-PGF2α) and ion m/z 573 (8-iso-PGF2α-d4 and IPF2α-VI-d4) were 
picked up by the detector, and amount of 8-iso-PGF2α was determined by comparing 
the peak area of 8-iso-PGF2α with combined peak area of 8-iso-PGF2α-d4 and 
IPF2α-VI-d4.  
 
Total arachidonate was analyzed after the analysis of F2-isoprostanes. 1 µl of 
further diluted derivatized sample was injected and the column temperature was kept 
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at 150 °C for 1 min, then increased to 260 °C at a speed of 20 °C/ min, and then held 
10 mins at 260 °C. Ion m/z 303 (for arachidonate) and ion m/z 311 (arachidonic 
acid-d8) was picked up by detector and amount of arachidonic acid was determined by 
comparing peak area of arachidonate and arachidonic acid-d8.  
 
COPs were analyzed by a Hewlett–Packard 5890 II gas chromatograph connected 
with a Hewlett–Packard 5975 mass selective detector. The gas chromatograph column 
used was a fused silica capillary column (15 m × 0.2 mm) coated with cross-linked 5% 
phenylmethylsiloxane (film thickness 0.33 μm). The mass spectrometer was set to 
electron ionization mode at 70 eV and the ion source and the quadrupole were set at 
230 and 150 °C. Helium flow rate was set to 0.8 ml/ min. 2 µl derivatized sample was 
injected and the column temperature was kept at 160 °C for 1 min, then increased to 
300 °C at a speed of 40 °C/ min, and then kept at 300 °C for 6 mins. Ions with 
different m/z were selected for each compound and internal standard as described in 
the previous publication (Lee et al., 2008). Quantification of each compound was 
done by comparing peak area of each compound with the internal standard. 
 
2.3.3.2 Determination of oxidative markers in liver. 
 
Determination of liver F2-isoprostanes, arachidonic acid, and COPs using GC-MS 
was performed as described in a previous publication (Jenner et al., 2008). Folch 
extract solution was made by mixing chloroform and methanol by 2:1 (v/v) with 
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0.005% BHT added. About 10 mg liver samples (exact weight recorded) were 
homogenized in 1 ml Folch extract solution at 4 °C and 250 µl PBS was added. The 
mixture was centrifuged at 1,000 g for 10 mins and organic layer was transferred to a 
new glass vial, which was dried under high-purity nitrogen gas. Samples were 
reconstituted with 1 ml PBS and heavy labeled isotopes were added (0.5 ng 
8-iso-PGF2α-d4, 0.5 ng IPF2α-VI-d4, and 10 µg arachidonic acid-d8, 20 ng 7α-OH 
cholesterol-d7, 10 ng 7-OH cholesterol-d7, 20 ng 7-ketocholesterol-d7, 20 ng 24-OH 
cholesterol-d7, 20 ng 27-OH cholesterol-d5, and 0.5 µg lathosterol-d4). Then the 
samples were mixed with 1 ml 1M KOH (in methanol) and hydrolyzed at 40 °C for 
30 mins after flushing with argon. 0.5 ml 0.4M sodium acetate was added and the 
samples were neutralized with 5M HCl. 
 
Anionic-exchange SPE cartridges were washed with 2 ml methanol and then with 
2 ml of 0.05M Tris-HCl. After loading samples, the column was washed with 2 ml of 
2% (v/v) ammonium hydroxide and 2 ml of methanol: 40mM formic acid (pH 4.5) 
(40: 60 v/v). COPs were eluted with 2 ml of 100% hexane and followed by 2 ml of 
hexane: ethyl acetate (70: 30 v/v). F2-isoprostanes and arachidonic acid were eluted 
with 1.8 ml of acetate: methanol: formic acid (89:10:1 v/v/v). The eluted samples 
were evaporated immediately under high-purity nitrogen gas.  
 
For COPs analysis, samples were derivatized with 25 µl acetonitrile and 25 µl 
BSTFA+1%TMCs at room temperature for 1 hour and then evaporated under nitrogen 
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gas. The derivatized samples were reconstituted in 30 l undecane before GC-MS 
analysis. For F2-isoprostanes and arachidonic acid analysis, samples were derivatized 
by 12.5 µl DIPEA (10% in acetonitrile) and 25 µl PFBBr (10% in acetonitrile) at 
room temperature for 30 mins and then evaporated under nitrogen gas. The 
derivatized samples were reconstituted in 12.5 l acetonitrile and silylated with 25 µl 
BSTFA+1%TMCs at room temperature for 1 hour, and then dried under nitrogen gas. 
Then the samples were reconstituted in 30 µl undecane before GC-MS analysis. 
 
GC-MS analysis of F2-isoprostanes, total arachidonate and COPs were performed 
in similar methods as the GC-MS analysis of oxidative stress markers in plasma (as 
described in section 2.3.3.1). 
 
 The amount of liver F2-isoprostanes, arachidonic acid, and COPs were 




 Aortic sections A, B, and C, and also liver and spleen tissues were cryo-sectioned 
for histological analysis. Samples were embedded in M-1 embedding matrix (Thermo 
Fisher Scientific Inc. MA, USA) with liquid nitrogen and stored at -80 °C. 
Cryo-sectioning was performed using Leica CM3050 S cryostat (Leica Microsystems 
GmbH). Chamber temperature was set to -18 °C and object temperature was set to 
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-23 °C. 16-µm-thick sections were obtained and placed on Superfrost* Ultra Plus 
adhesion slides (Thermo Fisher Scientific Inc.). Slides were stored at -80 °C before 
subsequent staining procedures. 
 
2.3.5 Hematoxylin and Eosin staining 
 
 Aortic, liver, and spleen sections were stained with hematoxylin and eosin stains 
to investigate histological changes. Hematoxylin solution consisted of 50 g/L 
aluminum potassium sulfate (alum), 1 g/L hematoxylin, 0.2 g/L sodium iodate, and 2% 
(v/v) acetic acid. The solution was then boiled, cooled, filtered and stored at room 
temperature. Eosin solution was prepared by mixing 250 ml eosin stock solution (10 g 
eosin in 1 L 80% ethanol) with 750 ml 80% ethanol and 5 ml glacial acetic acid, and 
stored at room temperature. 1 % (v/v) acid alcohol solution (for differentiation) was 
prepared by adding 1 ml 37% HCl into 100 ml 70% ethanol. 0.2% ammonia water 
solution was prepared by adding 2 ml concentrated ammonium hydroxide into 1 L 
distilled water. 
 
 Before the staining, slides were brought to room temperature and fixed by 
dipping into 95% ethanol for 2 mins. The slides were rinsed with distilled water, and 
then stained in hematoxylin solution for 10 mins. The nucleus was destained with 0.2% 
ammonia water solution for 15 seconds. Finally, cytoplasm was stained by dipping the 
slides in eosin solution for 10 seconds. The slides were subsequently dehydrated with 
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ethanol followed by xylene, and mounted with a resinous mounting medium. 
 
2.3.6 Oil red staining 
 
 Oil red O stock solution was prepared by dissolving 0.5 g oil red O in 100 ml 
isopropanol. Working solution was prepared from a mixture of 30 ml oil red O stock 
solution and 20 ml distilled water. Glycerine jelly mounting medium was prepared by 
dissolving 10 g gelatin in 60 ml distilled water, and then mixed with 70 ml glycerol 
and 0.25 g phenol. The mounting medium was stored at 4 °C. 
 
 Slides were brought to room temperature and fixed with 10% formalin. The slides 
were rinsed with 60% isopropanol and stained with freshly-made oil red O solution 
for 15 mins. The stained slides were rinsed briefly with 60% isopropanol and 
counter-stained with hemotoxylin solution for 5 seconds. The slides were then washed 
with distilled water and mounted in glycerine jelly mounting medium. 
 
2.3.7 Sirius red staining 
 
 Picro-sirius red solution was prepared by dissolving 1 g Sirius red F3B (direct red 
80; Sigma-Aldrich) in 1 L saturated picric acid solution and filtered before use. Slides 
were brought to room temperature, fixed in 95% ethanol for 2 mins, and rinsed with 
water. The slides were stained in picro-sirius red solution for 1 hour and then washed 
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with 0.5% (v/v) acetic acid. The stained slides were finally dehydrated in ethanol and 
xylene and mounted with resinous medium. 
 
2.3.8 Ferrozine assay for total iron content 
 
 The total iron content of liver and spleen tissue, blood plasma and food pellets 
were assessed using the ferrozine assay as described in Riemer et al., 2004. Briefly, 
about 10 mg either liver or spleen tissue was weighed and homogenized in 100 µl of 
50 mM sodium hydroxide. Samples were further diluted 2.5 times with 50 mM 
sodium hydroxide before the assay. Plasma samples were diluted 1 in 25 with 50 mM 
sodium hydroxide before the assay. Samples of the food pellets were firstly crushed 
into powder and about 10 mg crushed pellets from each dietary group was mixed with 
100 µl 50 mM sodium hydroxide. 100 µl ferric chloride standards (0 - 300 µM) were 
prepared by dilution from a stock solution (1mM ferric chloride in 10 mM HCl) with 
10 mM HCl solution.  
 
100 µl 10 mM HCl was added into each tissue, plasma or food pellet sample, 
while 100 µl 50 mM sodium hydroxide was added into each standard. 100 µl of 
freshly mixed solution of equal volume of 1.4 M HCl and 4.5% potassium 
permanganate (in water) was then mixed with each sample and standard, and the 
mixture was incubated for 2 hours at 60 °C with shaking at 500 rpm in a fume hood. 
After mixture cooled down to room temperature, 30 μl of iron-detection reagent (6.5 
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mM ferrozine, 6.5 mM neocuproine, 2.5 M ammonium acetate, and 1 M ascorbic acid) 
was added and the mixture vortexed and incubated at room temperature for 30 mins. 
Samples were centrifuged at 10,000 g for 5 mins and 100 µl of each sample was 
transferred to a microtitre plate in duplicates. The absorbance was measured at 550 
nm on a microplate reader. Total iron concentration was calculated based on the 
standard curve. Results of liver, spleen and brain tissues and food pellets were 
normalized to the exact sample weight. 
 
2.3.9 Cholesterol assay 
 
 Total cholesterol content of plasma and liver and brain tissue were measured via a 
fluorescent cholesterol quantitation assay (Cayman Chemical, Ann Arbor, MI, USA).  
 
10 mg liver sample were homogenized in 200 μl of chloroform: isopropanol: 
triton X-100 (7:11:0.1). The homogenate was centrifuged at 15,000 g for 10 mins. The 
organic layer was transferred into new glass vials and dried under high-purity nitrogen 
gas. Samples were then reconstituted by 200 µl cholesterol assay buffer.  
 
Plasma samples were diluted at 1:300, while extracted liver samples were diluted 
at 1:50, with cholesterol assay buffer. 50 µl of samples and standards were transferred 
into a 96-well plate with 50 µl of freshly made assay cocktail (150 µl cholesterol 
detector, 50 µl horseradish peroxidase, 50 µl cholesterol oxidase, and 5 µl cholesterol 
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esterase in 4.745 ml cholesterol assay buffer). The plate was covered and incubated in 
the absence of light for 30 mins at 37 °C. Fluorescence was measured using excitation 
at 535 nm and emission at 590 nm on a SpectraMax Gemini EM fluorescence 
microplate reader (Molecular Devices, Sunnyvale, CA). Cholesterol concentrations 
were calculated using standard curve. Liver cholesterol contents were normalized to 
exact sample weight. 
 
2.3.10 High performance liquid chromatography 
 
 Measurement of plasma ascorbic acid concentration was performed as described 
by Kand'ár et al., 2008. Briefly, 400 µl of cold 10% metaphosphoric acid was 
carefully added to 200 μl plasma samples. The mixture was incubated at 4 °C for 10 
mins and centrifuged at 22,000 g at 4 °C for 15 mins. Supernatants were filtered 
through a 0.20 µm nylon filter (4mm diameter, Corning Inc.) and transferred into 1 ml 
amber glass sample vials (Alltech) and purged briefly with nitrogen prior to analysis 
on the Agilent 1100 series high performance liquid chromatography (HPLC) system 
(Agilent Technologies, Santa Clara, CA, USA). HPLC for ascorbic acid was 
performed using isocratic elution on Discovery, 25 cm x 4.6 mm id, 5 µm C18 column 
(Supelco, Bellefonte, PA, USA) at 25 °C. The mobile phase is 25 mM sodium 
dihydrogenphosphate containing 5% methanol (v/v), pH 4.8, and the flow rate was 0.5 
ml/min, while UV detector was set at 265 nm. The concentration of ascorbic acid in 
plasma was calculated using a standard curve which was obtained from 2 – 250 µM 
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ascorbic acid standards. 
 
2.3.11 Alanine transaminase activity test 
 
 Plasma alanine transaminase (ALT) activity was measured using an ALT activity 
assay kit (Cayman Chemical, Ann Arbor, MI, USA). Briefly, plasma samples were 
thawed on ice and 150 µl of substrate, 20 µl of cofactor, and 20 µl of plasma (or 
positive control) were added into a 96-well plate. The plate was covered and 
incubated at 37 °C for 15 mins. 20 µl of ALT initiator was quickly added and 
absorbance at 340 nm was measured every minute over a 5 min duration. The level of 
ALT in plasma was determined by comparing the decreasing rate of plasma sample 
with that of the positive control (activity of ALT in positive control was 1 U). 
 
2.3.12 Gamma-glutamyl transpeptidase activity assay 
 
 Plasma gamma-glutamyl transpeptidase (GGT) activity was determined as 
described by Langford et al., 2007. Briefly, 100 µl plasma samples were thawed on 
ice and mixed with 1 ml GGT assay medium (1.8 mM γ-glutamyl-p-nitroanalide and 
20 nM glycyl-glycine in Tris-HCl buffer; pH 8.2). The mixture was incubated 4 hours 
at 37 °C, transferred to 96-well plate, and measured absorbance at 412 nm every 10 
mins on a microplate reader. GGT activities in plasma were calculated from the 
increasing rate of absorbance at 412 nm. 
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2.3.13 Transferrin ELISA 
 
 Plasma transferrin concentrations were determined with a guinea pig transferrin 
ELISA kit (antibodies-online GmbH, Aachen, Germany). Briefly, 100 µl of standards 
and samples were added to the pre-coated wells. 50 µl of conjugate was added to each 
well and the plate was covered and incubated at 37 °C for 1 hour. The plate was 
washed 5 times with wash buffer. 100 µl of substrate A and B (1:1) was subsequently 
added, and the plate was incubated at room temperature for 15 mins in the dark. 50 µl 
stop solution was added to each well. The absorbance was measured at 450 nm on a 
microplate reader. Plasma transferrin concentrations were calculated based on the 
standard curve obtained in the assay. 
 
2.3.14 Hepcidin ELISA 
 
 Plasma hepcidin concentration was determined using a guinea pig hepcidin 
ELISA kit (Novatein Biosciences, Cambridge, MA, USA). The samples were 
measured according to manufacturer’s protocol similarly to transferrin ELISA assay 
(see section 2.3.13). Plasma hepcidin concentrations were calculated using the 
standard curve obtained in the assay.  
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2.3.15 Protein carbonyl assay 
 
 Liver protein carbonyls were determined using a protein carbonyl assay kit from 
Cayman Chemicals (Ann Arbor, MI, USA). Briefly, about 200 mg liver sample (exact 
weight recorded) was homogenized in 1 ml cold 50 mM phosphate buffer (pH 6.7, 
containing 1 mM EDTA), and then centrifuged at 10,000 g for 15 mins at 4 °C. 
Nucleic acids were then removed by adding 110 µl 10% streptomycin (in 50 mM 
potassium phosphate, pH 7.2), and the mixture was incubated at room temperature for 
15 mins followed by centrifugation at 6,000 g for 10 mins at 4 °C. 200 µl supernatant 
was transferred to micro-centrifuge tubes and 800 µl 0.2% (w/v) 
2,4-Dinitrophenylhydrazine (DNPH) in 2.5M HCl was added into each sample and 
800 µl 2.5 M HCl was added into each control. Tubes were incubated in the dark for 1 
hour with vortex every 15 mins. 1 ml of 20% (w/v) TCA was added and the mixture 
was incubated on ice for 5 mins, then centrifuged at 10,000 g for 10 mins at 4 °C. 
Supernatant was discarded and the pellet was reconstituted with 1 ml of 10% (w/v) 
TCA. The solution was incubated on ice for 5 mins and centrifuged at 10,000 g for 10 
mins at 4 °C. Supernatant was again discarded and the pellet was washed twice with 1 
ml of ethanol/ethyl acetate (1:1) and centrifuged at 10,000 g for 10 mins at 4 °C. After 
the final wash, protein pellets were reconstituted in 500 µl of 6M guanidine 
hydrochloride and the tubes were centrifuged again at 10,000 g for 10 mins at 4 °C to 
remove any left debris. 220 µl of supernatant from sample and control was transferred 
to 96-well plate and absorbance at 370 nm was measured on a microplate reader. 
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Protein carbonyls were calculated by dividing the corrected absorbance (subtract 
absorbance of control from the absorbance of sample) by the extinction coefficient of 
DNPH at 370 nm (0.011 µM
-1
) and the dilution rate (500 µl/ 200 µl). The result was 
standardized to the exact weight of the liver samples. 
 
2.3.16 Ferritin ELISA 
 
 Liver ferritin content was determined using a guinea pig ferritin ELISA kit 
(MyBioSource, LLC; San Diego, CA, USA). Briefly, about 10 mg liver sample (exact 
weight recorded) was homogenized in 100 µl PBS (pH7.4). The samples were 
measured according to manufacturer’s protocol similarly to transferrin ELISA assay 
(see section 2.3.13). Ferritin concentrations were calculated using standard curve 
obtained in the assay. The results were standardized to the liver sample weight. 
 
2.3.17 Transferrin receptor-2 (TfR-2) ELISA 
 
 Liver TfR-2 contents were determined using a guinea pig transferrin receptor-2 
ELISA (MyBioSource, LLC; San Diego, CA, USA). Briefly, about 10 mg liver 
sample (exact weight recorded) was homogenized in 100 µl PBS (pH7.4). 
Measurement was performed similarly as transferrin ELISA assay (see section 2.3.13). 
TfR-2 concentrations were calculated using standard curve obtained in the assay. The 
results were standardized to the liver sample weight. 
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2.3.18 Heme determination assay 
 
 Heme contents in liver and spleen were determined using a protocol described by 
Morrison, (1965). Briefly, about 20 mg liver or spleen samples were homogenized in 
200 l PBS. 25 l of the homogenate or standard (0 – 80 g/ml hemin in PBS) was 
transferred to a new micro-centrifuge tube and diluted with 2 M oxalic acid to 500 l. 
Oxygen was removed by flushing the tubes with high-purity nitrogen gas. The 
mixture was then incubated at 105 °C for 30 mins. After cooled down, the mixture 
was diluted with distill water and fluorescence (protoporphyrin) was measured using 
Ex/ Em of 400/ 602 nm on a SpectraMax Gemini EM fluorescence microplate reader. 
Heme concentration was calculated using the standard curve obtained in the assay. 
The results were standardized to liver or spleen sample weight. 
 
2.3.19 Perl’s staining 
 
 Liver and spleen sections were stained with Perl’s staining method to demonstrate 
existence of hemosiderin. Briefly, slides were brought to room temperature and fixed 
with 95% ethanol for 2 mins. The slides were then put into freshly-made staining 
solution (2% potassium ferrocyanide in 2% HCl solution) with plastic tweezer and 
heated in microwave oven for 10 seconds. The slides were kept in warm staining 
solution for up to 3 mins and rinsed with distilled water. Then slides were 
counter-stained with 1 % neutral red solution for 1 min and rinsed with distilled water. 
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The slides were subsequently dehydrated in ethanol and xylene, and mounted with a 
resinous mounting medium. 
 
2.3.20 Hydroxyproline assay 
 
Liver hydroxyproline content was determined as described by Woessner et al., 
(1961). Briefly, about 20 mg liver sample was hydrolyzed in 1 ml 6M HCl for 3 hours 
at 130 °C. The hydrolysate was neutralized to pH 7.0 with 2.5 M NaOH and then 
diluted 40-fold with distilled water. 200 µl of diluted samples were transferred to a 
clean glass vial and mixed with 100 µl 0.05 M Chloramine-T solution (in pH 6.5 
buffer). The mixture was incubated at room temperature for 20 mins. 100 µl 3.15 M 
perchloric acid was further added and mixture was left to sit at room temperature for 5 
mins. 100 µl 20% p-dimethylaminobenzaldehyde solution (in 2-methoxyethanol) was 
added and mixture was incubated in a water bath at 60 °C for 20 mins and then cooled 
by running under tap water. 280 µl of the mixture was transferred into a 96-well plate, 
and the absorbance was measured at 560 nm on a microplate reader. Results were 
normalized against weight of liver samples. 
 
2.3.21 Iron/zinc analysis on aorta sections 
 
 Elemental analysis of unstained aortic sections were carried out as described in 
Ren et al. (2003) at the National University of Singapore, Centre for Ion Beam 
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Applications using a 2.1 MeV proton beam focused to a 1-μm spot size, with three 
complementary ion beam techniques: particle-induced X-ray emission, Rutherford 
backscattering spectrometry, and off-axis scanning transmission ion microscopy. 
 
2.3.22 Plasma HDL and LDL/VLDL assay 
 
 HDL and LDL/VLDL cholesterol levels in plasma were measured by a 
commercial assay (Biovision Inc., California, USA). Briefly, 100 µl 2× precipitation 
buffer was mixed with 100 µl plasma sample. The mixture was incubated at room 
temperature for 10 mins and then centrifuged at 2,000 g for 10 mins. The supernatant 
(HDL fraction) was carefully transferred to a new tube for cholesterol measurement. 
The pellet (LDL/VLDL fraction) was centrifuged at 2,000 g for 10 mins again and 
supernatant was carefully removed. The pellet was resuspended in 200 μl PBS for 
cholesterol measurement.  
 
For the cholesterol measurement, 50 µl of samples and standards were transferred 
to a 96-well plate and 50 µl of freshly made assay cocktail (2 µl cholesterol probe, 2µl 
enzyme mix, and 2 µl cholesterol esterase in 44 μl cholesterol assay buffer) was 
added. The plate was covered and incubated in the dark at 37 °C for 1 hour. 
Fluorescence was measured using Ex/ Em of 538 / 587 nm on a SpectraMax Gemini 
EM fluorescence microplate reader. Cholesterol concentrations were calculated based 
on the standard curve. 
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2.3.23 Liver HO-1 activity assay 
 
 Liver HO-1 activity was measured using a method modified from Tenhunen et al., 
(1968). Briefly, liver samples were homogenized in PBS and sonicated for 1 min. The 
homogenate was centrifuged at 10,000 g, 4 °C for 20 mins to remove cell debris. 
Supernatant was moved to new tubes for subsequent measurement. 2.5 M 
methemalbumin was prepared by firstly dissolving 13 mg hemin in 2.5 ml 0.1 M 
sodium hydroxide, which was then mixed with 5 ml 2% bovine albumin. The 300 μl 
incubation mixture consisted of 80 μl supernatant prepared previously, 170 μM heme, 
1.4 mM NADP, 4 mM glucose-6-phosphate, 0.2 units/ml glucose-6-phosphate 
dehydrogenase, 6.6 mM MgCl2, and 90 mM PBS. For negative controls, NADP and 
glucose-6-phosphate were replaced by PBS. The samples were incubated at 37 °C in 
dark for 30 mins. The bilirubin produced was extracted with 300μl chloroform and 
mixture was separated by centrifugation at 15,000 g, 4 °C for 5 mins. Absorbance at 










2.4 Data analysis 
 
 Statistical analyses were performed using IBM SPSS Statistics 19 (IBM Corp, 
NY, USA). Data are expressed as mean ± standard error of the mean (SEM), and 
P<0.05 was considered statistically significant. The mean values in food pellet 
analysis were calculated from triplicate experiments conducted on separate days using 
freshly prepared reagents. The mean values in other results were calculated from 7 
animals within each dietary group for a particular time point. Differences between 
dietary groups were evaluated using one-way ANOVA and Dunnett post hoc test for 
multi-group analysis (control as reference group). Spearman’s correlative quotient 





CHAPTER 3  
Basic observations in the guinea pig 
 
68 male Harley guinea pigs, weighing 250-500g, were randomly assigned to one 
of the ten groups for 0, 2, 4 or 6 months. Animals in 2, 4 and 6 month feeding 
durations were further assigned to control, moderate cholesterol or high cholesterol 
diet groups. No significant differences in appearance or behavior of the animals were 
observed between different groups with the exception of one animal from the 6-month 
high cholesterol group. It suffered significant weight and hair loss likely from an 
unrelated condition, and was euthanized and excluded from the analyses.  
 
3.1 Weight gain in guinea pigs and total food consumed 
 
 During the 6 month period of the animal trial, the body weights of the animals 
were recorded on alternate days and the average weight of each group was analyzed 
after the conclusion of the trial. As seen in Figure 3.1, there was a non-significant 
decrease in weight gained by moderate and high cholesterol group animals, which is 
consistent with a previous finding that guinea pigs decreased in weight when fed on a 
high cholesterol diet (Cook et al., 1951). The weight gains of the 2-month moderate 
cholesterol group animals were slightly higher than control and high cholesterol 
groups at the same time point, which could be partially explained by their high food 
consumption (see Table 3.1). By comparison, the high cholesterol group ate the least 
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amount of food, which could also partly explain their lower weight gains. However, 
none of these changes reached statistical significance (see Table 3.2 for the p-values).  
 
Table 3.1 Total food consumption of the three diet groups. Values were obtained by 
substracting the weight of left-over food after the study from the total weight of food.  










Figure 3.1 Average weight gains of 2-month (A), 4-month (B), and 6-month (C) 
groups. None of the differences was significant (n=7 in each group). See Table 3.2 for 







Table 3.2 P-values of one-way ANOVA analysis on weight gains of 2-month, 
4-month and 6-month groups (n=7 in each group). 
p-value Day 1 Day 3 Day 5 Day 7 Day 9 Day 11 Day 13 
2 months 0.948 0.574 0.458 0.388 0.392 0.430 0.191 
4 months 1.000 0.940 0.819 0.774 0.693 0.684 0.880 
6 months 1.000 0.945 0.537 0.804 0.185 0.184 0.305 
p-value Day 15 Day 17 Day 19 Day 21 Day 23 Day 25 Day 27 
2 months 0.267 0.327 0.35 0.353 0.523 0.417 0.300 
4 months 0.935 0.888 0.755 0.890 0.785 0.996 0.945 
6 months 0.272 0.405 0.241 0.286 0.247 0.111 0.211 
p-value Day 29 Day 31 Day 33 Day 35 Day 37 Day 39 Day 41 
2 months 0.405 0.431 0.676 0.365 0.554 0.754 0.535 
4 months 0.926 0.848 0.923 0.955 0.978 0.932 0.764 
6 months 0.247 0.217 0.338 0.257 0.300 0.285 0.504 
p-value Day 43 Day 45 Day 47 Day 49 Day 51 Day 53 Day 55 
2 months 0.338 0.310 0.228 0.353 0.232 0.314 0.226 
4 months 0.764 0.810 0.760 0.554 0.578 0.643 0.679 
6 months 0.420 0.324 0.271 0.301 0.333 0.493 0.266 
p-value Day 57 Day 59 Day 61 Day 63 Day 65 Day 67 Day 69 
2 months 0.122 
4 months 0.392 0.432 0.671 0.667 0.579 0.493 0.476 
6 months 0.262 0.375 0.347 0.325 0.320 0.148 0.470 
p-value Day 71 Day 73 Day 75 Day 77 Day 79 Day 81 Day 83 
4 months 0.473 0.423 0.314 0.377 0.396 0.336 0.307 
6 months 0.361 0.286 0.409 0.363 0.345 0.322 0.369 
p-value Day 85 Day 87 Day 89 Day 91 Day 93 Day 95 Day 97 
4 months 0.303 0.289 0.291 0.262 0.161 0.155 0.144 
6 months 0.280 0.288 0.265 0.180 0.248 0.258 0.250 
p-value Day 99 Day 101 Day 103 Day 105 Day 107 Day 109 Day 111 
4 months 0.122 0.126 0.146 0.136 0.126 0.115 0.109 
6 months 0.119 0.261 0.196 0.136 0.139 0.163 0.102 
p-value Day 113 Day 115 Day 117 Day 119 Day 121 Day 123 Day 125 
4 months 0.162 
6 months 0.070 0.059 0.123 0.129 0.180 0.212 0.260 
p-value Day 127 Day 129 Day 131 Day 133 Day 135 Day 137 Day 139 
6 months 0.151 0.150 0.124 0.160 0.148 0.123 0.342 
p-value Day 141 Day 143 Day 145 Day 147 Day 149 Day 151 Day 153 
6 months 0.207 0.197 0.170 0.178 0.251 0.208 0.211 
p-value Day 155 Day 157 Day 159 Day 161 Day 163 





3.2 Saliva stress marker concentrations and food lipid peroxidation levels and 
iron contents 
 
Animal cortisol levels were measured as a surrogate marker of stress to ensure 
that animals were not under undue stress. Salivary cortisol levels between animals did 
not significantly differ between the three dietary groups with P-values of 0.769, 0.439, 
0.295 and 0.579 for measurements at 0, 1.5, 3 and 4.5 months (one-way ANOVA). 
The cortisol levels generally increased throughout the duration of the experiment. 
This trend might be due to the restricted housing environment as the animals 




Figure 3.2 Average saliva cortisol concentrations of animals. None of the differences 
was significant (0 month: P=0.769; 1.5 months: P=0.439; 3 months: P=0.295; 4.5 






Lipid peroxidation levels as measured by the (unspecific) TBARS (thiobarbituric 
acid reactive substances) assay in the food pellets did not differ significantly between 
the three diets at the commencement (P=0.713, one-way ANOVA) and conclusion of 
the animal study (P=0.175, one-way ANOVA), reducing the chance of artifacts due to 
the consumption by the animals of an oxidized diet, which can itself cause 
pathological changes (Aw, 1998) (Figure 3.3). The TBARS assay was used because it 
detects oxidative damage to not only lipid, but also to many other constituents, such 
as sugars (Hermes-Lima et al., 1994) and DNA (Pogozelski et al., 1998). 
 
 
Figure 3.3 TBARS levels of diets at the commencement (A) (P=0.713, n=3 in each 
group, one-way ANOVA) and the conclusion (B) (P=0.175, n=3 in each group, 
one-way ANOVA) of the animal study.  
 
Results also revealed there were no significant differences in total iron content 






Figure 3.4 Total iron content of the three different diets (P=0.754, n=4 in each group, 
one-way ANOVA). 
 
3.3 Organ weight  
 
Liver weight was found to be significantly higher in 4- and 6-month high 
cholesterol groups and 6-months moderate cholesterol group, compared to control at 
the same time point (P<0.001, one-way ANOVA), when expressed as a % of total 
body weight (Figure 3.5A) or in absolute terms (Figure 3.6A). Similarly, the spleen 
weight was also greater in 2-, 4- and 6-month high cholesterol groups and 6-month 
moderate cholesterol group (P<0.01), when expressed as a % of total body weight 
(Figure 3.5B) or in absolute terms (Figure 3.6B). Heart weight was lower in 6-month 
moderate cholesterol group (P<0.05) and kidney weight was lower in 6-month high 
cholesterol group (P<0.05), when expressed in absolute terms (Figure 3.6C, E). 
However, there were no significant differences in heart, brain and kidney weights 
between the three dietary groups, when expressed as a % of total body weight (Figure 
















Figure 3.5 Organ weights of guinea pigs fed control diet, moderate cholesterol diet, 
and high cholesterol diet, expressed as a % of total body weight. **P<0.01 or 
***P<0.001 compared to control group at the same time point (n=7 in each group). 
See Table 3.3 for exact p-values of one-way ANOVA analysis on organ weights (when 







Table 3.3 P-values of one-way ANOVA analysis on organ weights, when expressed 
as a % of total body weight (n=7 in each group). 
Liver One-way ANOVA Moderate High 
2 months 0.271 0.618 0.191 
4 months <0.001 0.221 <0.001 
6 months <0.001 <0.001 <0.001 
Spleen One-way ANOVA Moderate High 
2 months 0.003 0.970 0.006 
4 months 0.004 0.568 0.003 
6 months 0.001 0.004 0.001 
Heart One-way ANOVA Moderate High 
2 months 0.328 0.484 0.254 
4 months 0.436 0.981 0.389 
6 months 0.050 0.080 0.927 
Brain One-way ANOVA Moderate High 
2 months 0.159 0.284 0.823 
4 months 0.753 0.696 0.981 
6 months 0.193 0.791 0.342 
Kidney One-way ANOVA Moderate High 
2 months 0.075 0.079 0.093 
4 months 0.268 0.256 0.290 


















Figure 3.6 Organ weights of guinea pigs fed control diet, moderate cholesterol diet, 
and high cholesterol diet, expressed as absolute terms. *P<0.05, **P<0.01 or 
***P<0.001 compared to control group at the same time point (n=7 in each group). 
See Table 3.4 for exact p-values of one-way ANOVA analysis on organ weights (when 







Table 3.4 P-values of one-way ANOVA analysis on organ weights, when expressed 
as absolute terms (n=7 in each group). 
Liver One-way ANOVA Moderate High 
2 months 0.430 0.367 0.510 
4 months <0.001 0.465 <0.001 
6 months <0.001 0.005 <0.001 
Spleen One-way ANOVA Moderate High 
2 months 0.008 0.937 0.009 
4 months 0.010 0.558 0.006 
6 months 0.002 0.003 0.005 
Heart One-way ANOVA Moderate High 
2 months 0.204 0.152 0.350 
4 months 0.572 0.919 0.483 
6 months 0.038 0.043 0.055 
Brain One-way ANOVA Moderate High 
2 months 0.824 0.809 1.000 
4 months 0.471 0.369 0.792 
6 months 0.081 0.051 0.565 
Kidney One-way ANOVA Moderate High 
2 months 0.190 0.873 0.146 
4 months 0.427 0.390 0.460 




CHAPTER 4  
PATHOLOGICAL CHANGES IN PLASMA AND BLOOD VESSELS 
 
Since guinea pigs have been suggested to be a more “realistic” model of 
atherosclerosis (Fernandez et al., 2006), we planned to use this model to study 
oxidative damage and metal ion distribution during the development of atherosclerotic 
plaques generated in the aortas of these animals.  
 
4.1 Plasma cholesterol and lipoprotein profile 
 
Since plasma cholesterol is important in the promotion of atherosclerosis (see 
section 1.2.2), plasma total cholesterol and lipoprotein profiles were measured. 
Plasma cholesterol levels were significantly higher in moderate cholesterol and high 
cholesterol groups at 2-, 4- and 6-month time points (P<0.001, Figure 4.1), and levels 
were found to generally increase with duration of feeding. This result indicated that 
the guinea pig can develop a pro-atherosclerotic plasma lipoprotein profile when 
challenged with 0.17% and 0.33% dietary cholesterol, consistent with previous 
studies (Lin et al., 1992; Fernandez, 2001). The 2-month moderate cholesterol group 
revealed an abnormally high cholesterol level (Figure 4.1) which might perhaps be 





Figure 4.1 Plasma total cholesterol concentrations. **P<0.01 or ***P<0.001 
compared to control group of the same time point (n=7 in each group). See Table 4.1 
for exact p-values of one-way ANOVA analysis on plasma total cholesterol 
concentrations. 
 
Table 4.1 P-value of one-way ANOVA analysis on plasma total cholesterol 
concentrations of moderate and high cholesterol groups (n=7 in each group).  
p-value 
Moderate High 




<0.001 0.002 <0.001 <0.001 <0.001 <0.001 
 
Similarly to total cholesterol, plasma LDL-cholesterol levels were significantly 
elevated in the moderate and high cholesterol groups at 2, 4, and 6 months (P<0.001, 
Figure 4.2). The abnormally high LDL-cholesterol of the moderate cholesterol group 
at 2 months was related to the high total plasma cholesterol (see Figure 4.1) and as 
mentioned earlier could be due to their excessive food consumption compared to other 
groups (see Table 3.1). Plasma HDL-cholesterol was significantly elevated in the high 
cholesterol group at 2, 4 and 6 months (P<0.001), but not significantly so in the 








ratio of LDL-cholesterol to HDL-cholesterol was significantly higher in both 
moderate and high cholesterol groups (P<0.001), also suggestive of an atherosclerotic 
plasma lipoprotein profile in those animals (Figure 4.2). Those results are consistent 







Figure 4.2 Plasma LDL-cholesterol (A), HDL-cholesterol (B), and ratio of 
LDL-cholesterol to HDL-cholesterol (C). *P<0.05, **P<0.01 or ***P<0.001 
compared to control group of the same time point (n=7 in each group). See Table 4.2 
for exact p-values of one-way ANOVA analysis on plasma LDL-cholesterol, 




















Table 4.2 P-value of one-way ANOVA analysis on plasma LDL-cholesterol, 
HDL-cholesterol, and ratio of LDL-cholesterol to HDL-cholesterol of moderate and 
high cholesterol groups (n=7 in each group).  
p-value 
Moderate High 
2 months 4 months 6 months 2 months 4 months 6 months 
LDL-cholesterol <0.001 0.014 0.006 <0.001 <0.001 <0.001 




<0.001 0.020 0.003 0.089 0.001 0.006 
 
4.2 Plasma markers of oxidative stress 
 
Oxidative stress plays an important role in atherosclerosis development (see 
section 1.3.2.1). Oxidative stress in the plasma was assessed by measuring levels of 
oxidative stress markers, such as COPs and F2-isoprostanes, and arachidonic acid 
using GC-MS (Figure 4.3). Analysis of the COPs revealed that 7α-OH cholesterol 
concentrations were significantly elevated in the high cholesterol group at 4 months 
(P<0.01) and 6 months (P<0.001), and in the moderate cholesterol group at 4 months 
(P<0.05) and also tended to be elevated at all other points. 7β-OH cholesterol and 
7-ketocholesterol concentrations were also significantly higher in high cholesterol 
group at 4 months (P<0.05 and P<0.01, respectively). F2-isoprostanes concentrations 
were significantly higher in moderate cholesterol groups at 4 months (P<0.05), 
compared to the control group at 2, 4 and 6 months (see p-value in Table 4.3), and 
also tended to be elevated at all other points. Those results indicate an overall increase 




As seen with cholesterol levels, the concentration of COPs also increased with 
feeding duration in moderate and high cholesterol groups (Figure 4.3). Likewise, 
F2-isoprostanes levels also increased along with feeding duration in all the three 
dietary groups, however, only moderate cholesterol fed animals at 4 months were 
observed to be significant relative to controls of the same time point (P<0.05, Figure 
4.3D). 27-OH cholesterol was not detectable in guinea pig plasma. Arachidonic acid 
concentrations were significantly elevated in the moderate cholesterol group at 2 
months (P<0.001) (Figure 4.3E), and as mentioned earlier could be due to their 
















Figure 4.3 Plasma COPs (A-C), F2-isoprostanes (D), and arachidonic acid (E) 
concentrations. *P<0.05, **P<0.01 or ***P<0.001 compared to control group of the 
same time point (n=7 in each group). See Table 4.3 for exact p-values of one-way 
ANOVA analysis on plasma COPs, F2-isoprostanes, and arachidonic acid 
concentrations. 
 
Table 4.3 P-value of one-way ANOVA analysis on plasma COPs, F2-isoprostanes, and 




2 months 4 months 6 months 2 months 4 months 6 months 
7α-OH cholesterol 0.875 0.050 0.080 0.451 0.002 <0.001 
7β-OH cholesterol 1.000 0.686 0.176 0.888 0.041 0.064 
7-ketocholesterol 0.226 0.204 0.427 0.103 0.006 0.097 
F2-isoprostanes 0.141 0.042 0.198 0.342 0.077 0.388 







After standardizing the COPs to plasma cholesterol concentration, the increases 
of COPs in moderate and high cholesterol groups disappeared, suggesting perhaps 
that the overall increase in plasma COPs concentrations could possibly be due to the 
increase in plasma total cholesterol concentrations. However, this increase in 
oxidatively modified cholesterol is still indicative of increased cardiovascular and 
atherosclerotic risk burden to the animal (see section 1.3.2.1). F2-isoprostanes levels 
are sometimes standardized with plasma arachidonic acid concentrations, as they were 
formed via free radical-initiated peroxidation of arachidonic acid (Milne et al., 2005). 
The significant increase in F2-isoprostanes with duration of feeding was unchanged 
after standardization, however, the difference between dietary groups was no longer 
significant (2-month: P=0.688; 4-month: P=0.153; 6-month: P=0.908, one-way 




Figure 4.4 Plasma F2-isoprostanes before (A) and after (B) standardization. *P<0.05 
compared to control group of the same time point (n=7 in each group). See Table 4.4 
for exact p-values of one-way ANOVA analysis on plasma F2-isoprostanes before and 
after standardization. 
 
Table 4.4 P-value of one-way ANOVA analysis on plasma F2-isoprostanes before and 
after standardization of moderate and high cholesterol groups (n=7 in each group).  
p-value 
Moderate High 
2 months 4 months 6 months 2 months 4 months 6 months 
Before 
standardization 
0.141 0.042 0.198 0.342 0.077 0.388 
After 
standardization 







4.3 Atherosclerotic changes in artery 
 
It was claimed that “guinea pigs present early atherosclerotic development and 
fatty streak accumulation after 12 weeks when challenged with increasing amounts of 
dietary cholesterol in the range of 2000 mg per day consumption by humans” 
(Fernandez, 2001). However, unexpectedly, after histological investigation of a large 
number of sections from the aortas (segments A, B, and C) of all 68 animals we 
examined, very few atherosclerotic lesions were found, and with no significant 
difference in the number and development of plaques observed between moderate and 
high cholesterol diet fed animals relative to age-matched controls (Table 4.5).  
 
A review of the literature has shown that indeed numerous studies in guinea pigs 
have revealed a wide array of similarities to humans. In addition, guinea pigs seem to 
have similar responses to dietary challenges with high fat and cholesterol, degree of 
fatty acid saturation, carbohydrate restriction, soluble fiber, antioxidants, or 
pharmaceutical interventions. However, despite the large number of guinea pig studies, 
very few report observations of atherosclerotic lesions and there have been no reports 
of advanced lesions being seen in the guinea pig (see our detailed review in Ye et al., 
2012). Whilst the guinea pig model makes sense because of its many similarities in 
lipoprotein profile and cholesterol metabolism to humans, the difficulties in 
developing atherosclerotic pathology may not make this the best model for studying 
this condition. As it stands, current evidence raises doubt as to whether guinea pigs 
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could serve as a realistic model for atherosclerosis. 
  
Table 4.5 Number of apparent aortic atherosclerotic lesions in each group. 
Diets           Time 0 month 2 months 4 months 6 months 
Control diet 
0/5 
0/7 1/7 2/7 
Moderate cholesterol diet 1/7 2/7 2/7 
High cholesterol diet 1/7 2/7 3/6
#
 
Number of animals with suspected atherosclerotic lesions / total number of animals in the group. 
#one animal was excluded from the analysis due to its severe illness. 
 
Atherosclerotic lesions are usually identified by thickening of the artery wall. 
Other obvious hallmarks of atherosclerotic plaques included histological observations 
of foam cells, necrotic core, and calcification (Figure 4.5). Among the few suspected 
plaques found in cholesterol-fed guinea pigs in our study, histological examination 
revealed a locally thickened artery wall consisting of irregularly arranged foam cells, 
or normally-looking non-foamy cells (Figure 4.5). As with atherosclerosis in many 
other animal models (including rats, mice and rabbits), guinea pigs do not develop a 
diffuse intimal thickening (Figure 4.5), a characteristic observation prior to 
atherogenesis in humans (Nakashima et al., 2008). In addition, human atherosclerotic 
plaques usually have a clear lipid core between tunica media and a fibrous cap (Hegyi 







Figure 4.5 Suspected aortic atherosclerotic lesions from various sections (A, B, and C) 
from the aortas of all 68 animals we examined. Sections were stained with 
hematoxylin-eosin. Black arrow indicate possible foam cells (A) and necrotic core (B) 






Nuclear microscopy (in collaboration with Prof Frank Watt’s group, Centre for 
Ion Beam Applications, Department of Physics, National University of Singapore) of 
selected “plaque-like” lesions only revealed a trend of increasing iron and decreasing 
zinc in lesion area compared to non-lesion area. However, this difference was not 
significant (iron: P=0.168; zinc: P=0.101; Student’s t-test) (Figure 4.6 table). The 
increasing trend of iron and decreasing trend of zinc is similar to what we have 
previously observed in rabbits fed on a high cholesterol diet (Ren et al., 2003, 2005 & 
2007), although in these animals clear and distinctive atherosclerotic lesions were 
observed. 
Investigation of normal aortic sections without plaques revealed a trend to 
increasing calcium and chloride but no significant changes in iron and zinc (Figure 
4.6A & B). The observation of increasing calcium in plaque-like areas may be 
perhaps indicative of early calcification as this was not observed in normal aortic 
sections without plaques. The chloride was found to increase in sections with and 
without plaques. However although this may indicate an accumulation of salt we are 






Figure 4.6 Nuclear microscopy results of normal artery (A) and suspected plaque (B) 
from 6-month groups. See Table 4.6 for exact p-values of Student’s t-test analysis on 
nuclear microscopy results (n=4 in each group). 
 
Table 4.6 P-value of Student’s t-test analysis on nuclear microscopy results of normal 
artery and suspected plaque from 6-month groups (n=4 in each group). 











Staining of aortic sections which indicated increased iron and decreased zinc 
(sections without lesions), with Oil red O, revealed areas of positive staining on 
arterial endothelium in both moderate and high cholesterol groups, which may be 
indicative of lipid deposition and early atherosclerotic development. In comparison, 
no staining was observed in sections from the control diet group and 0-month time 
control group (Figure 4.7). This may also be indicative of endothelial dysfunction 
however there was no clear evidence of more advanced lesions.  
 
 
Figure 4.7 Artery atherosclerotic changes in section A of 0-month (A), 6-month 
control (B), 6-month moderate cholesterol (C), and 6-month high cholesterol (D) 
groups. Arrows indicate lipid deposition on artery endothelium (Oil red staining 
positive). Representative slides of five aortic sections obtained from each of three 
different animals from each group. 
 





results (histology and nuclear microscopy), indicate that atherosclerotic changes 
generated by feeding guinea pigs a 0.17% and 0.33% cholesterol diet, if any, are 
limited to endothelial dysfunction and lipid deposition. Furthermore, there was little 
direct evidence that those changes would finally develop into more advanced 
atherosclerotic plaques similarly found in humans, or how long this development 
would take. A much longer animal study (e.g. up to 1-2 years) would be required to 
clarify the above questions, which would be however very challenging due to high 
cost of animal housing and food and as will be discussed later the animals may well 
die before that of other complications, namely liver failure. 
 
4.4 Plasma ascorbic acid level 
 
It is known that similar to humans, guinea pigs cannot synthesize vitamin C and 
therefore require vitamin C in the diet (Sauberlich, 1978), making guinea pigs a good 
model for studying vitamin C uptake. The three different diets in our study contained 
equal amounts of vitamin C (1.5 g/kg, see Table 2.1). Plasma ascorbic acid levels 
were significantly lower in the high cholesterol group at 4 and 6 months (P=0.044 and 
P=0.039, respectively, one-way ANOVA), but not in the moderate cholesterol group 
(Figure 4.8). This result could perhaps be partially explained by relatively low food 
consumption in high cholesterol groups (see Table 3.1). A previous study also found 
that vitamin C levels significantly decreased in brain and plasma when guinea pigs 
were fed with diets rich in fat and cholesterol, which is possibly due to an increase in 





Figure 4.8 Plasma ascorbic acid concentrations. *P<0.05 compared to control group 
of the same time point (n=7 in each group). See Table 4.7 for exact p-values of 
one-way ANOVA analysis on plasma ascorbic acid concentrations. 
 
Table 4.7 P-value of one-way ANOVA analysis on plasma ascorbic acid 
concentrations of moderate and high cholesterol groups (n=7 in each group).  
p-value 
Moderate High 
2 months 4 months 6 months 2 months 4 months 6 months 





Although guinea pigs were suggested to be a good model for studying 
atherosclerosis (Fernandez, 2001) due to a wide array of similarities in lipid profile 
and cholesterol metabolism to human, when fed with high cholesterol and fat diet, 
there was no conclusive evidence to suggest that the guinea pigs developed 




of increasing iron and decreasing zinc observed in aorta. Considering the long 
duration of this animal study, the result raises doubt as to whether guinea pigs could 
serve as a realistic model for atherosclerosis. Indeed, a review of the literature 
revealed that very few guinea pig studies reported observations of atherosclerotic 
lesions and there have been no reports of advanced lesions being seen in the guinea 
pig (Ye et al., 2012). This result also highlighted that similarities in lipid profile 
between guinea pigs and humans do not necessarily lead to similar atherosclerotic 
pathology, and the complexities of apply the results of animal studies to humans.  
 
Study with a much longer duration will be needed to see whether the guinea pigs 
could develop advanced plaques. However, it is very likely that the guinea pigs will 
die from NAFLD before advanced plaques can be seen (further discussed in chapter 
5). 
 
Cholesterol-fed guinea pigs showed elevated plasma total cholesterol and 
atherosclerotic plasma lipoprotein profile, which is consistent with previous studies 
(Lin et al., 1992 & 1995). Although absolute levels of plasma oxidative damage 
markers were increased, overall plasma oxidative stress did not increase equally, and 
it is possible that some or all the increase in markers could be due to an increase of the 
precursor compounds. Plasma ascorbic acid levels of cholesterol-fed guinea pigs were 




CHAPTER 5  
PATHOLOGICAL CHANGES IN LIVER AND SPLEEN 
 
During the sacrifice of animals, very obvious changes in appearance and weights 
(Figure 3.5A, 3.6A) of the animal livers from moderate and high cholesterol groups 
(as early as 2 months) were observed as compared to control animals. This 
observation led us to further investigate the pathological changes in the liver, and later 
investigate the enlarged spleen (Figure 3.5B, 3.6B) which was also seen in moderate 
and high cholesterol group animals.  
 
5.1 Hepatic steatosis 
 
5.1.1 Histological changes 
 
Non-alcoholic fatty liver disease (NAFLD) is characterized by excessive 
accumulation of triglyceride as lipid droplets in hepatic cells (Li et al., 2009). Oil red 
staining revealed large areas of positive staining in liver sections from moderate and 
high cholesterol groups (Figure 5.1C & E), indicating hepatic lipid accumulation in 
those animals, which was not found in the control group (Figure 5.1A). H&E staining 
results showed many vacuoles in moderate and high cholesterol groups, which are 
likely to be lipid depositions dissolved by alcohol during the cleaning steps of H&E 
staining (Figure 5.1D & F), and were not found in the control group (Figure 5.1B). 
98 
 
The histological observations in the liver of moderate and high cholesterol fed 





Figure 5.1 Liver lipid depositions, using Oil red O staining (left column) or H&E 
staining (right column), sections were obtained from 6-month control (A & B), 
moderate cholesterol group (C & D), and high cholesterol group (E & F). 
Representative slides of eight liver sections obtained from each of three different 








5.1.2 Liver damage markers 
 
Liver injury is an important step in the development from simple hepatic steatosis 
to non-alcoholic steatohepatitis (NASH) (Browning et al., 2004). Plasma alanine 
transaminase (ALT) and gamma-glutamyl transpeptidase (GGT) activities are 
commonly used as markers of liver damage (Gary-Bobo et al., 2007), both of which 
were found to be significantly elevated in the plasma of high cholesterol fed animals 
(ALT: P<0.01; GGT: P<0.05, two-way ANOVA) (Figure 5.2). These markers were 
also elevated in the moderate cholesterol group, however these differences were not 
significant. The results suggest there is an increase in hepatic injury in moderate and 





Figure 5.2 Plasma ALT activity (A) (moderate: P=0.333; high: P=0.003; n=7 in each 
group) and GGT activity (B) (moderate: 0.065; high: P=0.038; n=7 in each group). 
Statistical analysis: two-way ANOVA with Dunnett post hoc test for multi-group 







5.2 Liver cholesterol and markers of oxidative stress  
 
Cholesterol is considered an important risk factor for NAFLD (Wouters et al., 
2008; Subramanian et al., 2011). Cholesterol is primarily obtained through de novo 
synthesis (as illustrated in Figure 1.2) or from dietary sources (see section 1.2.1). 
Liver is one of the major organs of cholesterol synthesis, and the only site for 
conversion of cholesterol to bile acids (Spady et al., 1985), and the site for VLDL and 
HDL synthesis and LDL clearance (see section 1.2.1). Liver cholesterol content 
within each diet group was found to increase with duration of feeding and was 
significantly higher in moderate cholesterol and high cholesterol groups at 2, 4, and 6 




Figure 5.3 Liver total cholesterol contents. ***P<0.001 compared to control group at 
the same time point (n=7 in each group). See Table 5.1 for exact p-values of one-way 









Table 5.1 P-value of one-way ANOVA analysis on liver total cholesterol contents of 
moderate and high cholesterol groups (n=7 in each group).  
p-value 
Moderate High 
2 months 4 months 6 months 2 months 4 months 6 months 
Liver total 
cholesterol content 
<0.001 <0.001 <0.001 <0.001 <0.001 <0.001 
 
Previous studies have shown that dietary cholesterol intake is important in the 
onset and progression of NAFLD in non-obese NAFLD patients (Yasutake et al., 
2009), which is thought to rely on activation of the LXRα-SREBP-1c pathway by 
COPs and subsequent increase in the synthesis of fatty acids in liver (see details in 
section 1.2.3). Liver COPs, lathosterol, F2-isoprostanes, and arachidonic acid were 
measured by GC-MS as shown in Figures 5.4 and 5.5. Similar to the results found in 
plasma, 27-OH cholesterol was also not detectable in guinea pig liver samples. Liver 
COPs levels (7α-OH cholesterol, 7β-OH cholesterol, 7-ketocholesterol, and 24-OH 
cholesterol) were significantly higher in moderate and high cholesterol groups at 2, 4 
and 6 months (Figure 5.4A-D). Liver lathosterol contents were also significantly 
higher in the moderate cholesterol group at 4 months and in the high cholesterol group 
at 2 and 6 months (Figure 5.4E), indicating an increase of liver cholesterol synthesis 
in those groups. This is consistent with previous findings in humans that cholesterol 
synthesis is higher in NAFLD patients (Simonen et al., 2011). 
 
As seen with the plasma, the liver COPs increased with increasing liver 
cholesterol levels and feeding duration in moderate and high cholesterol groups 
(Figure 5.4). F2-isoprostanes content also tended to increase along with feed duration 
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in all the three dietary groups (Figure 5.4F), however, no significant difference was 
observed between the three dietary groups. Previous studies have also shown an 
increase in liver F2-isoprostanes content in rats fed with a high fat diet (Zhu et al., 
2008). The 0-month group revealed a high F2-isoprostanes level which declined with 
time. There may be a few reasons for this. Firstly, 0-month group animals arrived long 
before the animals in other groups and may have been consuming a different food 
prior to their purchase, which may have greater oxidation. Secondly, 0-month group 
animals came from a different animal batch which may have a higher baseline 
F2-isoprostanes levels. Thirdly, 0-month group animals were sacrificed not long after 
arriving in their new environment, and might not be fully accommodated which led to 
higher oxidative stress levels in liver.  
 
Liver arachidonic acid contents were significantly lower in the moderate and high 
cholesterol groups at 2, 4, and 6 months (P<0.001, Figure 5.4G). This result is 
consistent with previous findings that there was a decrease in liver arachidonic acid 
and an increase in liver linoleic acid, in rats fed with cholesterol-added diets, which 
was related to an alteration in the desaturase activities (Muriana et al., 1992). 
 







































Figure 5.4 Liver COPs (A-D), lathosterol (E), F2-isoprostanes (F), and arachidonic 
acid (G) contents, when expressed in absolute terms. *P<0.05, **P<0.01 or 
***P<0.001 compared to control group at the same time point (n=7 in each group). 
See Table 5.2 for exact p-values of one-way ANOVA analysis on liver COPs, 
lathosterol, F2-isoprostanes, and arachidonic acid contents. 
 
Table 5.2 P-value of one-way ANOVA analysis on liver COPs, lathosterol, 
F2-isoprostanes, and arachidonic acid contents of moderate and high cholesterol 
groups, when expressed in absolute terms (n=7 in each group).  
p-value 
Moderate High 
2 months 4 months 6 months 2 months 4 months 6 months 
7α-OH cholesterol 0.480 0.017 0.010 <0.001 <0.001 <0.001 
7β-OH cholesterol 0.620 0.091 0.024 <0.001 <0.001 <0.001 
7-ketocholesterol 0.809 0.103 0.008 <0.001 <0.001 <0.001 
24-OH cholesterol 0.192 0.001 <0.001 0.001 0.003 <0.001 
Lathosterol 0.490 0.038 0.162 0.007 0.125 0.026 
F2-isoprostanes 0.683 0.150 0.922 0.916 0.794 0.284 
Arachidonic acid <0.001 0.004 0.007 0.001 <0.001 0.025 
 
However, after standardizing with liver cholesterol concentration, the increasing 
trend of COPs with feeding duration in moderate and high cholesterol groups was no 
longer significant, with the exception that 7α-OH cholesterol, 7β-OH cholesterol and 
7-ketocholesterol were significantly higher in high cholesterol groups at 6 months 










a higher oxidative burden. After standardizing with plasma arachidonic acid 
concentration, the change in F2-isoprostanes remained the same and despite the 
increasing trend to a rise, still no significant difference was found among dietary 
groups (Figure 5.5D). 
 









Figure 5.5 Liver COPs (A-C) when expressed as ratios to liver total cholesterol 
contents and F2-isoprostanes (D) when expressed as ratios to liver arachidonic acid 
contents. *P<0.05, **P<0.01 or ***P<0.001 compared to control group at the same 
time point (n=7 in each group). See Table 5.3 for exact p-values of one-way ANOVA 
analysis on liver COPs when expressed as ratios to liver total cholesterol contents and 
F2-isoprostanes when expressed as ratios to liver arachidonic acid contents. 
 
Table 5.3 P-value of one-way ANOVA analysis on liver COPs when expressed as 
ratios to liver total cholesterol contents and F2-isoprostanes when expressed as ratios 
to liver arachidonic acid contents (n=7 in each group). 
p-value 
Moderate High 
2 months 4 months 6 months 2 months 4 months 6 months 
7α-OH cholesterol 0.033 0.459 0.078 0.864 0.997 <0.001 
7β-OH cholesterol 0.172 0.774 0.088 0.949 0.110 <0.001 
7-ketocholesterol 0.003 0.709 0.050 0.021 0.955 <0.001 










5.3 Iron regulation 
 
5.3.1 Hepatic iron contents 
 
Early clinical studies revealed an increase in hepatic iron levels in NASH (Bacon 
et al., 1994), and a possible role of iron-related liver injury in the development of 
NASH was suggested (George et al. 1998). However, subsequent studies showed 
controversial results (see section 1.4.2.2). Our results found that liver total iron 
content was significantly increased in the moderate cholesterol group at 4 and 6 
months, and in the high cholesterol group at 2, 4, and 6 months (P<0.001, Figure 5.6), 
relative to the controls, indicating an accumulation of iron.  
 
 
Figure 5.6 Liver total iron contents. **P<0.01 or ***P<0.001 compared to control 
group at the same time point (n=7 in each group). See Table 5.4 for exact p-values of 










Table 5.4 P-value of one-way ANOVA analysis on liver total iron contents of 
moderate and high cholesterol groups.  
p-value 
Moderate High 
2 months 4 months 6 months 2 months 4 months 6 months 
Liver total iron 
contents 
0.341 0.002 0.004 <0.001 <0.001 0.004 
 
Interestingly, total iron content of the liver was found to have a similar pattern to 
liver cholesterol content (see Figure 5.3). A correlation analysis was conducted and 
results showed a strong correlation between liver total iron and cholesterol contents 
(R
2
=0.6109, Figure 5.7A), indicating that those two parameters might be related in the 
pathway that leads to the development of NAFLD. This correlation was further 
increased (R
2
=0.9375) by investigating the correlation of the mean values in each 





Figure 5.7 Correlation between liver total iron and cholesterol contents. (A) 
correlation analysis using data from individual animals; (B) scatter pattern of data 
across the four major groups (zero-month, control, moderate, and high); (C) 
correlation analysis using mean value of each of the 10 groups (divided by different 
time and diets), including 0-month, 2-month control, moderate, and high, 4-month 






5.3.2 Hepatic heme, ferritin, and hemosiderin. 
 
The majority of iron in the body can be found in heme and the storage proteins 
ferritin and hemosiderin (Lieu et al., 2001). In order to find out the origin of the 
excess iron in the liver of moderate and high cholesterol fed animals, the heme 
content of the livers was measured. The results showed that heme contents in fact 
significantly decreased in moderate and high cholesterol groups at 4 and 6 months 




Figure 5.8 Liver heme contents. *P<0.05 or ***P<0.001 compared to control group 
at the same time point (n=7 in each group). See Table 5.5 for exact p-values of 
one-way ANOVA analysis on liver heme contents. 
 
Table 5.5 P-value of one-way ANOVA analysis on liver heme contents of moderate 
and high cholesterol groups (n=7 in each group).  
p-value 
Moderate High 
2 months 4 months 6 months 2 months 4 months 6 months 
Liver heme 
contents 








Ferritin is a major form of iron storage in vivo, and iron stored in this form can be 
easily re-used by the body (Wang et al., 2010). The major iron storage sites are liver, 
spleen, and bone marrow (see section 1.4.3). Under normal conditions, excess iron 
will lead to an increase in ferritin but not in other iron-containing proteins such as 
hemoglobin or myoglobin, while iron deficiency will lead to release of iron from 
ferritin (Harrison et al., 1996). The ferritin expression in liver was measured using a 
ferritin ELISA kit (MyBioSource, LLC), with polyclonal antibodies targeting guinea 
pig ferritin protein. The results showed that there was no significant difference 
between different dietary groups at 2, 4, and 6 months (Figure 5.9), with the exception 
of the high cholesterol group at 4 months which was found to have elevated levels of 
liver ferritin (P<0.05). Hence there was no marked increase in liver ferritin. 
 
 
Figure 5.9 Liver ferritin levels as determined by ELISA. *P<0.05 compared to 
control group at the same time point (n=7 in each group). See Table 5.6 for exact 





Table 5.6 P-value of one-way ANOVA analysis on liver ferritin levels of moderate 
and high cholesterol groups (n=7 in each group).  
p-value 
Moderate High 
2 months 4 months 6 months 2 months 4 months 6 months 
Liver ferritin 
levels 
0.510 0.077 0.895 0.994 0.028 0.851 
 
Hemosiderin is another iron storage protein in tissues in vivo, and usually exists 
as large insoluble complexes. The iron present in hemosiderin is released much more 
slowly than ferritin and hence is harder to be re-used by the body, however it helps to 
protect the body against damage from reactive species generated from free iron 
through Fenton chemistry (O'Connell et al., 1986). Hemosiderin normally exists in 
macrophages as an iron supplier for erythrogenesis in spleen and bone marrow 
(Sadahira et al., 1999), but little is normally found in liver. In iron-overload diseases 
such as hemochromatosis, however, large amount of excess iron are stored in liver as 
hemosiderin (Bonkovsky, 1991), and hemosiderin deposition in hepatocytes rather 
than Kupffer cells (macrophages in liver) is a typical hallmark of hemochromatosis 
(Batts, 2007). Hemosiderin is difficult to quantify with current techniques and has 
been mainly investigated using Perl’s staining (Brown et al., 2011). Perl’s staining of 
the liver sections in our animals revealed a clear difference between moderate and 
high cholesterol groups compared with controls. In sections from 6-month moderate 
and high cholesterol animals, clear blue positive staining could be seen, while little 
such staining was visible in the control group (Figure 5.10, 5.11, 5.12). These results 
together with our observation of decreased liver heme and unchanged ferritin content, 
suggest that the excess liver iron exists as hemosiderin. This result agrees with the 
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coexistence of limited oxidative damage and higher iron content in liver, because iron 
stored in hemosiderin is very stable and poorly redox-active (Hoffman et al., 1991; 





Figure 5.10 Hemosiderin in liver (control group). Both sections were stained with 
Perl’s staining protocol, presented at 20× (A) or 60× (B) magnification. 
Representative slides of six sections obtained from each of three different animals 






Figure 5.11 Hemosiderin in liver (moderate cholesterol group). Both sections were 
stained with Perl’s staining protocol, presented at 20× (A) or 60× (B) magnification. 
Black arrow indicates blue positive staining which indicates in situ hemosiderin. 
Representative slides of six sections obtained from each of three different animals 






Figure 5.12 Hemosiderin in liver (high cholesterol group). Both sections were stained 
with Perl’s staining protocol, presented at 20× (A) or 60× (B) magnification. Black 
arrow indicates blue positive staining which indicates in situ hemosiderin. 
Representative slides of six sections obtained from each of three different animals 






5.3.3 Transferrin, hepcidin, and iron concentrations in plasma 
 
Hepcidin is a hormone secreted by liver which decreases iron absorption by the 
intestine by promoting the degradation of the iron transporter, ferroportin-1 (Fleming 
et al., 2001). Measurement of plasma hepcidin by ELISA revealed that levels were 
significantly decreased in the moderate and high cholesterol groups at 4 and 6 months 
(P<0.05, Figure 5.13). In addition, plasma total iron concentrations were significantly 
increased in moderate and high cholesterol groups (6-month moderate: P<0.05; 
4-month high: P<0.05; 6-month high: P<0.001; Figure 5.14), consistent with our 
finding of decreased plasma hepcidin. 
 
 
Figure 5.13 Plasma hepcidin levels. *P<0.05 or **P<0.01 compared to control group 
at the same time point (n=7 in each group). See Table 5.7 for exact p-values of 








Table 5.7 P-value of one-way ANOVA analysis on plasma hepcidin levels of 
moderate and high cholesterol groups (n=7 in each group).  
p-value 
Moderate High 
2 months 4 months 6 months 2 months 4 months 6 months 
Plasma hepcidin 
levels 




Figure 5.14 Plasma total iron concentration. *P<0.05 or ***P<0.001 compared to 
control group at the same time point (n=7 in each group). See Table 5.8 for exact 
p-values of one-way ANOVA analysis on plasma total iron levels. 
 
 
Table 5.8 P-value of one-way ANOVA analysis on plasma total iron levels of 
moderate and high cholesterol groups (n=7 in each group).  
p-value 
Moderate High 
2 months 4 months 6 months 2 months 4 months 6 months 
Plasma total iron 
levels 
0.074 0.398 0.011 0.212 0.020 0.001 
 
 
Recent studies have shown that in addition to the major iron transporters in the 
circulation, transferrin is also an upstream regulator of hepcidin (Bartnikas, 2012; 
Gkouvatsos et al., 2012). Similarly to hepcidin, the results demonstrated that plasma 





cholesterol group at 2 months, Figure 5.15). This decrease in plasma transferrin could 
perhaps be due to liver damage leading to a decrease in transferrin synthesis. The 
decrease in plasma transferrin levels may be the cause of the decrease in plasma 
hepcidin levels. However, it is also possible that the liver damage may directly result 
in decreased hepcidin secretion into the circulation.  
 
 
Figure 5.15 Plasma transferrin levels. *P<0.05 compared to control group at the same 
time point (n=7 in each group). See Table 5.9 for exact p-values of one-way ANOVA 
analysis on plasma transferrin levels. 
 
 
Table 5.9 P-value of one-way ANOVA analysis on plasma transferrin levels of 
moderate and high cholesterol groups (n=7 in each group).  
p-value 
Moderate High 
2 months 4 months 6 months 2 months 4 months 6 months 
Plasma transferrin 
levels 






5.3.4 Transferrin receptor-2 expression in liver 
 
Many types of cells take up iron from the circulation via transferrin receptors. 
There are two types of transferrin receptors, transferrin receptor 1 (TfR-1) and 
transferrin receptor 2 (TfR-2). TfR-1 is responsible for iron uptake in the majority of 
cells, expression of which is inversely regulated by cellular iron levels through a 
post-transcriptional mechanism (see section 1.4.3). TfR-2 is mostly expressed in liver 
and is regulated by plasma transferrin saturation levels (Nadadur et al., 2008). In 
addition to iron uptake, TfR-2 is also found to play a role in the regulation of plasma 
hepcidin levels (Subramaniam et al., 2002; Trinder et al., 2003) and hence their levels 
in the liver were investigated. Measurement of TfR-2 using an ELISA assay revealed 
no significant differences in TfR-2 levels between the three dietary groups (2-month: 
P=0.353; 4-month: P=0.426; 6-month: P=0.394; one-way ANOVA) (Figure 5.16), 
indicating that the decrease in plasma hepcidin was not due to a change in hepatic 





Figure 5.16 Transferrin receptor-2 expression in the liver of the three dietary groups. 
None of the differences was significant (n=7 in each group). See Table 5.10 for exact 
p-values of one-way ANOVA analysis on liver transferrin receptor-2 levels. 
 
Table 5.10 P-value of one-way ANOVA analysis on liver transferrin receptor-2 levels 
of moderate and high cholesterol groups (n=7 in each group).  
p-value 
Moderate High 
2 months 4 months 6 months 2 months 4 months 6 months 
Liver transferrin 
receptor-2 levels 
0.428 0.436 0.684 0.300 0.998 0.300 
 
5.3.5 Heme oxygenase-1 expression in the liver 
 
Heme oxygenase-1 (HO-1) is an enzyme which degrades heme into iron, carbon 
monoxide, and biliverdin, which subsequently is converted to bilirubin by biliverdin 
reductase (Sass et al., 2012). HO-1 is expressed in many types of cell. HO-1 can be 
induced by heme, which depends on several heme-responsive elements (Shan et al., 
2000). HO-1 has been linked to cytoprotection and can decrease liver damage in 
several models of acute and chronic hepatic inflammation (Sass et al., 2012). HO-1 
induction can reduce the total number of hepatic leukocytes, macrophage and other 
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immune cells (Barikbin et al., 2012). HO-1 induction in hepatic stellate cells can 
reduce their activity and hence reduce hepatic fibrosis (see section 1.4.3). To 
investigate whether HO-1 degradation of hemoglobin, from erythrocyte recycling, is 
in part responsible for the elevated iron and decreased heme, we measured HO-1 
activity in the liver tissue. Our results showed that HO-1 activity was slightly higher 
in moderate and high cholesterol groups, although the differences were not significant 
given the high variability between animals (2-month: P=0.793; 4-month: 0.642; 
6-month: P=0.155; one-way ANOVA), indicating that the increase in hepatic iron of 
moderate and high cholesterol groups may be due to excessive heme breakdown by 
this enzyme (Figure 5.17). However, this is probably not the main pathway of hepatic 
iron accumulation in our study. 
 
 
Figure 5.17 Liver HO-1 activity. None of the differences were significant (n=7 in 






Table 5.11 P-value of one-way ANOVA analysis on liver HO-1 activity of moderate 
and high cholesterol groups (n=7 in each group).  
p-value 
Moderate High 
2 months 4 months 6 months 2 months 4 months 6 months 
Liver HO-1 
activity 




 Hepatosplenomegaly is defined as simultaneous enlargement of liver and spleen 
(Hyams et al., 1987). Hepatosplenomegaly can happen in schistosomiasis and malaria 
(Wilson et al., 2011), acute viral hepatitis (Ishii et al., 2003), and NAFLD (Tsushima 
et al., 2000). 
 
5.4.1 Hydroxyproline content in liver 
 
Previous studies have shown that spleen can be enlarged in NAFLD, which is 
associated with obstruction of hepatic blood circulation, subsequently leading to 
portal vein hypertension (Tsushima et al., 2000). Liver fibrosis was also shown to be 
related to spleen enlargement (Bolognesi et al., 2002). Liver hydroxyproline content 
was measured as an indicator of collagen in tissue and marker of hepatic fibrosis, and 
was found to be significantly increased in the moderate and high cholesterol groups at 
2, 4, and 6 months (P<0.001, Figure 5.18), indicating development of fibrotic liver in 
those animals. Sirius red staining of liver sections also suggested significant 
proliferation of connective tissue (bright red staining of collagen fibers) in those 
126 
 
groups (Figure 5.19B & C). These results suggest that spleen enlargement observed in 
moderate and high cholesterol groups could be due to liver fibrosis and subsequent 
portal vein hypertension. 
 
 
Figure 5.18 Liver hydroxyproline contents measured by a hydroxyproline assay 
(section 2.3.20). ***P<0.001 compared to control group at the same time point (n=7 
in each group). See Table 5.12 for exact p-values of one-way ANOVA analysis on 
liver hydroxyproline contents. 
 
Table 5.12 P-value of one-way ANOVA analysis on liver hydroxyproline contents of 
moderate and high cholesterol groups (n=7 in each group).  
p-value 
Moderate High 
















Figure 5.19 Liver collagen staining, by Sirius red staining. Sections from 6-month 
control (A), moderate cholesterol group (B), and high cholesterol group (C), presented 
at 20× magnification. Representative slides of six sections obtained from each of three 






5.4.2 Spleen histological changes 
 
No significant differences in spleen histology were found between dietary groups 
(Figure 5.20). Neither white nor red pulp areas were significantly increased in the 
enlarged spleens of moderate and high cholesterol animals (Figure 5.20). Hence, 
despite an enlargement of the spleen the ratio between the white and red pulp 





Figure 5.20 Spleen histology of 6-month control group (A), moderate cholesterol 
group (B), and high cholesterol group (C). Sections were stained with H&E and 
presented at 20× magnification. Representative slides of five sections obtained from 






5.4.3 Spleen iron content 
 
Spleen total iron contents tended to increase with the duration of feeding in all 
groups, however no significant differences were observed between the three dietary 
groups (2-month: 0.056; 4-month: 0.877; 6-month: 0.517; one-way ANOVA) although 
there was a slight decrease in moderate and high cholesterol animals (Figure 5.21). 
This could be due to an unchanged total iron despite an increase in the spleen volume 
in the moderate and high cholesterol animals. Similarly, spleen heme contents were 
significantly lower in the high cholesterol group at 2 months (P<0.01), 4 months 
(P<0.05), and 6 months (P<0.05), and also slightly lower in the moderate cholesterol 
group, although the differences were not significant (Figure 5.22). Those results 
showed that the spleen iron content was not significantly influenced by the abnormal 
iron regulation in the liver of moderate and high cholesterol groups. 
 
 
Figure 5.21 Spleen iron contents. None of the differences was significant (n=7 in 





Table 5.13 P-value of one-way ANOVA analysis on spleen iron contents of moderate 
and high cholesterol groups (n=7 in each group).  
p-value 
Moderate High 
2 months 4 months 6 months 2 months 4 months 6 months 
Spleen iron 
contents 




Figure 5.22 Spleen heme contents. *P<0.05 or **P<0.01 compared to control group 
at the same time point (n=7 in each group). See Table 5.14 for exact p-values of 
one-way ANOVA analysis on spleen heme contents. 
 
Table 5.14 P-value of one-way ANOVA analysis on spleen heme contents of 
moderate and high cholesterol groups (n=7 in each group).  
p-value 
Moderate High 
2 months 4 months 6 months 2 months 4 months 6 months 
Spleen heme 
contents 






5.4.4 Hemosiderin in spleen 
 
As further confirmation of the normal iron regulation in the spleen, Perl’s staining 
of spleen sections showed no significant differences between all dietary groups 
(sample collected from 6-month control, moderate and high cholesterol groups) 
(Figure 5.23). Hemosiderin was widely scattered in red pulp (but not found in white 
pulp) in all three dietary groups (Figure 5.23). This result suggests an accumulation of 
iron as hemosiderin in normal spleen which might be used as an iron supplier for 
erythrogenesis (Sadahira et al., 1999). However, this normal deposition may have 
masked any small changes in hemosiderin that could have been caused by abnormal 





Figure 5.23 Hemosiderin in spleen. Histology of 6-month control group (A), 
moderate cholesterol group (B), and high cholesterol group (C), stained with Perl’s 
stain and presented at 10× magnification. Representative slides of five sections 








Iron accumulation in NAFLD has been observed for a long time (Bacon et al., 
1994; George et al. 1998; Sumida et al. 2003) but its mechanism is not well 
understood. Our studies suggest a cause-consequence relationship between cholesterol, 
NAFLD and iron in guinea pigs. Similar to the findings that dietary cholesterol intake 
is important in the onset and progression of NAFLD in humans (Yasutake et al., 
2009), cholesterol-fed guinea pigs showed significant hepatic steatosis and fibrosis 
which are also typical pathological changes in human NAFLD, and hepatic iron 
accumulation which is similar to the findings of elevated hepatic iron content in 
NAFLD patients (Bacon et al., 1994). 
 
Our studies also suggest the possible mechanism of this pathological process 
which involves iron metabolism changes. The development of fatty livers in 
cholesterol-fed animals was accompanied by liver damage which may have led to the 
decrease in expression of transferrin and hepcidin. In addition, decreased plasma 
transferrin may contribute to the decrease in plasma hepcidin. Decreased secretion of 
hepcidin by liver could possibly lead to a raised iron absorption through the intestines 
and therefore raising plasma iron concentrations, which may be in part responsible for 
the hepatic iron accumulation in those animals in the form of hemosiderin. This is 
likely the main pathway which may possibly cause hepatic iron accumulation in 
NAFLD patients. In addition, increased HO-1 levels in liver could also play a part in 
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the hepatic iron accumulation of the cholesterol-fed guinea pigs due to excessive 
heme breakdown, although it is probably a minor pathway (see Figure 5.24 for an 
illustration of the suggested pathways).  
 
Interestingly, this pathway is similar to what has been found in hepatitis C, 
alcoholic fatty liver disease, and hemochromatosis, all of which involve abnormalities 
in hepcidin metabolism and subsequently, iron overload. Previous studies have 
suggested that hepatitis C may induce a serum hepcidin regulation failure and that the 
decreased hepcidin secretion by liver may be responsible for the increased hepatic 
iron in hepatitis C patients (Nagashima et al., 2006; Fujita et al., 2007). A full 
recovery of hepcidin production was observed after hepatitis C was eradicated (Fujita 
et al., 2008). Hepcidin levels were also shown to decrease in alcoholic fatty liver 
disease, which is probably the cause of high hepatic iron deposition in the patients 
(Bridle et al., 2006; Ohtake et al., 2007). Hemosiderin deposition in the liver is found 
to be a common feature of iron overload (Stremmel et al., 2007). 
 
Whether the elevated iron plays a role in the second stage of NAFLD or diseases 
in other organs requires further investigation. Raised plasma iron could be another 
issue, since the raised plasma iron might result in iron accumulation in other organs. 
This includes the arterial wall and endothelium as seen with atherosclerosis. Our 
previous work has shown that iron accumulates in aortic atherosclerotic lesions in 
cholesterol-fed rabbits, and iron depletion could inhibit the development of those 
136 
 
lesions (Ren et al., 2003; Ren et al., 2005). Whilst it remains unclear how the iron 
accumulates (not from excess iron in the animal diets as we have observed), the 
accumulation may primarily commence from dysregulation of iron uptake in the liver.  
 
Our studies have established that the guinea pigs are a suitable model for studying 
NAFLD. However, further studies to observe the effect of iron chelators on the 
development of NAFLD in the guinea pig model could help clarify the pathological 
role of iron in the disease, and whether the prevention of hepatic iron and plasma iron 
accumulation will help slow down or even reverse the development of NAFLD. 
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